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ABSTRACT 
1 
2 
3 
Purpose:  Currently, heart transplantation and mechanical circulatory 
support (MCS) are the preferred treatments for end stage heart failure.  However, 
these therapies are associated with a shortage of donor organs, a 5-yr survival 
rate of 80%, and adverse events associated with long-term MCS usage.  To 
overcome these limitations, new clinical paradigm is proposed using a 
combination therapy of MCS and extracellular matrix (ECM) injection therapy to 
promote myocardial recovery.  
Methods:  The experimental design consisted of a control (no therapy, 
n=10) and 3 test groups: (1) ECM only (n=2); (2) MSC (HVAD) only (n=2); and 
(3) HVAD + ECM (n=2) in a 60-day chronic ischemic heart failure (IHF) bovine 
model.  The ECM (CorMatrix®, Atlanta, GA) was injected into the ischemic 
region of myocardium and the HVAD (HeartWare®, Miami Lakes, FL), a 
centrifugal continuous flow device was implanted.  Cardiovascular efficacy and 
function were quantified using by serial measurements of hemodynamics, 
echocardiogram and fluoroscopy imaging, fluorescent microsphere perfusion, 
and BrdU labeling (myocyte proliferation).   
vi 
 
Results:  The study demonstrated HVAD+ECM therapy may provide 
greatest benefits toward myocardial remodeling and recovery.  The preliminary 
data indicates feasibility in the new treatment method and a larger sample size is 
needed to determine significance. 
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I. INTRODUCTION 
1 
2 
3 
A. Heart Failure Background 
1 
2 
Cardiovascular disease (CVD) is among the most prevalent and costly 
diseases plaguing the United States.  In 2010, it was reported that CVD affects 
more than 80 million people in the United States, and had an associated mortality 
of 500,000 deaths per year[2, 3]. In fact, CVD is the leading cause of morbidity 
and mortality in the country for both men and women[4].  Although it is estimated 
that more than 70% of cardiovascular disease can be prevented through 
avoidance of cardiovascular risk factors, such as smoking, poor diet, and 
insufficient exercise, only 5% of middle-age and older adults are considered to 
have avoided the associated risk factors to the ideal level[5].   
By 2030, the prevalence of CVD is expected to increase by 25%[6] as 
more and more of the population is diagnosed with diabetes, metabolic 
syndrome, and other CVD risk factors[7].  Because of these trends, CVD will 
increasingly be the United States’ most deadly healthcare issue.  As a 
consequence, CVD is also one of the most economically draining diseases.  The 
number of inpatient cardiovascular operations has increased by 30% in the last 
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decade[2].  The American Heart Association has estimated that the direct and 
indirect cost of CVD and stroke in the United States was more than $316.6 billion 
in 2012[2]. 
The term “cardiovascular disease” encompasses many diseases that 
involve the heart and vasculature system.  These include atherosclerosis, 
coronary heart disease, cardiomyopathy, cardiac dysrhythmias, and valvular 
heart disease[8].  Heart failure (HF) is often considered a related syndrome[3] 
because it has a specific set of features and symptoms but multiple possible 
causes.  CVD most often affects patients through heart failure[3].  With the 
emergence of a CVD precursor, such as hypertension or acute myocardial 
infarction, a cascade of destructive structural, functional, and biologic changes is 
initiated[9].  The destructive changes ultimately lead to the development of HF as 
the heart struggles to meet the body’s metabolic demand.  Some of the 
underlying causes and reactive changes involved in the development of chronic 
HF include ischemic insult, poor myocardial perfusion, impaired cardiac function, 
and cardiac remodeling[10].  It is estimated that HF affects 5 million people in the 
Unites States, and severe class IV heart failure HF is associated with a 1-year 
mortality rate of 60%[11]. 
1 
2 
3 
B. Left Ventricle (LV) Remodeling 
1 
2 
Progressive heart failure is characterized by a pathological remodeling of 
myocardial muscle associated with contractile dysfunction and systolic  
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expansion[12].  Myocardial remodeling, thought to be the result of myocardial 
infarction and acute ischemia, adversely affects ventricular function[13]. During 
the original insult, myocytes undergo necrosis, which is followed by edema and 
inflammation of the myocardium. Proliferating fibroblasts then invade the necrotic 
tissue, and matrix metalloproteinases degrade the myocardial extracellular 
matrix. The fibroblasts then deposit high density collagen tissue.  This process 
creates non-contractile scar tissue[13].  
Both the infarcted and non-infarcted regions undergo a gradual 
lengthening process, which causes the ventricle to lose contractile power. The 
high-density collagen scar tissue has a greater tensile strength than healthy 
tissue and, as a result, the infarcted tissue begins to lengthen and lose 
thickness[14]. This process causes significant expansion of the infarcted region 
in the hours and days following the original insult.  Within weeks, the entire 
ventricle dilates. Because of slippage between muscle fiber bundles, the number 
of myocytes is reduced across the region. That contributes further to the 
lengthening, thinning, and loss of contractility of the ventricle [15]. Figure 1 Part 
(A) shows the progression of myocardial expansion at the site of an apical 
infarction.  
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Figure 1:  Part  (A) Ventricular Remodeling after Infarction; Part (B) Remodeling in Diastolic and 
Systolic Heart Failure [3] 
Ventricular remodeling in infarcted and non-infarcted regions is also 
thought to be a response to myocardial dysfunction.  The magnitude of 
ventricular remodeling is positively associated with the extent of the initial 
damage at the time of infarct.  The loss of contractility and dilation at systole, or 
systolic heart failure, acutely decreases the heart’s stroke volume, ejection 
fraction, and cardiac output. In order to adapt to decreased contractility, the heart 
must compensate: the ventricle dilates in size to achieve a restored stroke 
volume and cardiac output, although total ejection fraction decreases to 
abnormally low values.  Figure 1 Part (B), right panel, shows complete left 
ventricle dilation in systolic heart failure.  In order to maintain cardiac function, 
distension of the viable myocardium, utilization of the Frank-Starling mechanism, 
and positive chronotropy and inotropy occur[13].  In the Frank-Starling 
mechanism, diastolic distension during filling increases myosin-actin interaction 
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and maximizes contractility.  The chronotropic and inotropic activity helps 
compensate for poor cardiac function by increasing the frequency of beats and 
myocardial contractility, thereby increasing stroke volume and cardiac output. 
Although this compensatory mechanism helps restore adequate function 
in the short term, long term dilation has been shown to increase diastolic and 
systolic wall stress, which stimulates further ventricular dilation[16]. That process 
results in the progressive nature of heart failure. The surviving myocytes have 
been shown to undergo hypertrophy, increasing cellular volume by up to 78%, in 
order to compensate for the amplified wall stress[17].  However, cellular 
hypertrophy is inadequate to compensate for myocardial loss and does not 
balance out the mounting effects of ventricular dilation[17].  Rather, the 
cardiomyocytes experience more stress as the ventricle enlarges to compensate 
for poor myocardial performance and the contractile fibers in each sarcomere are 
stretched to the limit and, in turn, lose more mechanical contractile power.  
Figure 1 Part (B), middle panel, depicts left ventricle myocardial hypertrophy.  In 
diastolic heart failure, which is a response to hypertension rather than to 
infarction, the myocardium undergoes extreme hypertrophy to compensate for 
systemic resistance to flow[3].  Although systolic function is preserved, diastolic 
function is hindered.  Diastolic heart failure may account for 20–50% of the heart 
failure population[3]; however, this paper will continue to focus on classical 
systolic heart failure. 
As the heart undergoes remodeling, not only do the ventricular walls begin 
to dilate and enlarge, the heart also begins to lose its compact and conical 
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shape, becoming more globular.  This negatively impacts the effectiveness of the 
mitral valve.  Many heart failure patients begin to develop mitral regurgitation as 
the geometric relationship between the mitral valve leaflets and the papillary 
muscles, which are responsible for holding the valve in place, are drastically 
altered[18].  The regurgitation of blood during systole only adds to the 
ineffectiveness of cardiac function during heart failure, as blood is recirculated 
back into the atrium.  It is readily apparent that the compensatory effects of heart 
failure compound and promote further structural damage, gradually worsening 
the patient’s condition. 
1 
2 
3 
C. Current Therapeutic Approaches 
1 
2 
The treatment of heart failure is a complex process that involves many 
levels of intervention to prevent the development and progression of ventricular 
remodeling and cardiac dysfunction. Figure 2 shows the standard clinical 
treatments required at each stage of heart failure. 
 
Figure 2:  Stages of Heart Failure and Treatment Options for Systolic Heart Failure [3] 
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Stage A (stage I) is characterized by a high risk for the development of 
heart failure without any symptoms or structural damage.  Patients at this stage 
are treated for hypertension or other cardiovascular disease precursors, with the 
intention of preventing any pathological structural remodeling.  Intervention at this 
stage has shown to decrease the incidence of heart failure by 30–50%[19].  
Stage B (stage II) involves the structural damage associated with heart failure but 
with no symptoms.  These patients may have undergone a previous myocardial 
infarction but the associated structural changes have not yet physically affected 
their quality of life.  At this stage, physicians use several objective methods to 
diagnose the level of heart failure including  electrocardiogram to detect electrical 
abnormalities and cardiac imaging via echocardiography and chest x-ray to 
detect pulmonary congestion or an enlarged heart[20].   
Stage C (stage III) patients have structural damage and physical 
symptoms.  The symptoms commonly involve breathlessness and fatigue at rest 
or during moderate exercise, which result from poor cardiac function[21].  These 
patients receive aggressive pharmaceutical treatment and may undergo mitral 
valve or cardiac resynchronization therapy. Lastly, stage D (stage IV) patients 
experience refractory symptoms, extreme fatigue even at rest and require 
hospitalization.  Surgical intervention and specialized care is necessary for 
patient survival. The following sections examine the common approaches to 
treating heart failure. 
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1. Pharmacological Treatments 
Researchers have isolated and studied several important factors in heart 
failure as avenues for possible treatment, although the exact mechanism of 
action for each is not yet completely understood. It is thought that, to halt the 
progression and possibly reverse heart failure and the associated remodeling, 
there needs to be a decrease in myocardial wall stress and therefore a reduction 
in resistance to flow. With an increased emphasis on the relationship between 
altered cardiovascular dynamics and the neuro-hormonal effects of them, 
pharmaceutical treatments are currently being developed to alleviate the heart’s 
increased workload.   
Figure 3 diagrams the pathophysiology and neuro-hormonal relationship in 
progressive heart failure.  During heart failure, poor cardiac function causes a 
drop in systemic pressures. Because of a pathologic unloading at the sites 
cardiovascular baroreceptors (blue circles), an afferent sensory signal (black 
arrow) is transmitted to the cardio-regulatory center in the central nervous 
system.  This causes the activation of the sympathetic nervous system (green 
arrows) and the stimulation of a hormonal response (blue arrows) to drive up 
blood pressure to stimulate increased atrial filling[22]. These sympathetic signals, 
in turn, place more of a burden on the failing heart, adding to the cyclical nature 
of progressive heart failure. 
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Figure 3:  Pathophysiology of Heart Failure [22] 
With the neuro-hormonal response in mind, several pharmaceuticals have 
been designed to disrupt the hormonal pathway of heart failure.  For example, 
beta-blockers slow heart rate and decrease blood pressure by inhibiting the 
sympathetic β-adrenergic mechanisms[23].  Beta-blockers stop the sympathetic 
nervous system from promoting the release of vasoactive chemicals, such as 
renin, which stimulate vasoconstriction and tachycardia and only serve to 
exacerbate ventricular remodeling[3].  Angiotensin-converting-enzyme (ACE) 
inhibitors also decrease the afterload by blocking the renin-angiotensin-
aldosterone system[3]. Likewise, diuretics encourage excess fluid elimination, 
effectively decreasing blood pressure.  Aldosterone, which causes water 
retention and increased blood pressure, is often elevated in heart failure patients. 
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Aldosterone acts to increase the afterload and the stress on the myocardium. 
Specific inotropic agents and chemicals, such as digoxin, can be used to 
maintain optimum heart rate, contractility, and ventricle filling times[24]. Digoxin 
acts as a NA+/K+ ATPase inhibitor that increases intracellular Ca2+, which causes 
an increase in contractility and duration of systole, effectively decreasing the 
heart rate while maintaining optimum stroke volume[25].  Although the use of 
pharmaceuticals is generally the first course of treatment in every heart failure 
case, many patients’ conditions progress into dangerous pathologies and require 
specialized care and surgical intervention.   
2. Heart Transplant 
Today, heart transplantation remains the ideal destination therapy for 
advanced and refractory heart failure.  It has an associated 50% 10-year survival 
rate[26], which greatly exceeds the 60% 1-year survival rate for stage IV patients 
without transplantation. However, this treatment method has dramatic limitations 
that prevent its widespread use.  Because of an extreme shortage of viable 
human donor hearts, less than 4,000 cardiac transplant surgeries are performed 
in the United States each year[27].  In addition, patients who receive a heart 
transplant must remain immunosuppressed to prevent rejection.  That can leave 
already compromised patients susceptible to life-threatening diseases and 
complications[26].  Because of the scarcity of donor hearts and the associated 
limitations, alternative replacement hearts have been developed in the form of 
mechanical circulatory support. 
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3. Mechanical Circulatory Support  
The first mechanical circulatory support (MCS) device, a cardiopulmonary 
bypass machine, was developed in 1953 to support patients during open heart 
surgery[28].  The development of artificial hearts for use in heart failure patients 
started in the 1960’s with the National Heart Institute’s establishment of the 
Artificial Heart Program.  At this time, research was focused on producing a 
complete heart replacement, or total artificial heart (TAH). TAH devices were 
originally developed for use until such a time that a replacement donor heart 
became available.  This method is known as bridge to transplant therapy (BTT). 
The TAH devices presented problems with durability and biocompatibility.  The 
complex moving parts in the TAH devices invited the distinct possibility of 
premature mechanical failure. TAH devices, such as the SynCardia’s CardioWest 
TAH (FDA BTT approved in 2004), are only designed to support a patient for a 
matter of months until transplantation[29].  These devices are used in cases in 
which the patient is at severe risk of mortality within 30 days.   Although the TAH 
method had great success supporting patients until transplant, the devices had 
limitations that encouraged researchers to explore different avenues.   
By the 1980s, the first generation of ventricular assist devices (VAD) was 
created. Instead of aiming to completely replace the heart, researchers 
developed a method of unloading the stressors associated with heart failure.  
They developed devices to divert blood flow from the ventricle to a secondary 
mechanical pump and return it back to the aorta.  The bypass of flow essentially 
relieves the cardiac demands on the ventricle, and completely disrupts the 
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destructive signals associated with LV remodeling and dilation.  The first 
generation of VADs were pulsatile, large, and often extracorporeal, meaning the 
pump remained outside the body.  The devices that were fully implantable were 
installed in the abdomen below the diaphragm.  These devices advanced in 
biocompatibility as new materials were developed that were inert in the body, 
such as Heartmate XVE’s unique surface texturing that reduced the risk of stroke 
from emboli[30]. The HeartMate XVE, along with other first-generation VADs, 
were conceived as a destination therapy. However, these devices still faced 
durability issues and were primarily used as BTT devices[31].  
With the need for smaller, implantable, and more durable VADs, 
researchers developed a second generation.  The new generation abandoned 
the pulsatile pumping mechanisms of the first generation, such as pneumatic 
actuators. Instead, they utilized axial rotors that continuously propelled blood.  
With this new mechanism, researchers could miniaturize VADs and even develop 
pediatric pumps. These constitute the first generation of MCS that was approved 
for destination therapy (DT), such as the Jarvik 2000 (EU approved DT in 2005). 
With success in the second generation, a third and fourth generation of VADs are 
now being developed.  These devices utilize centrifugal flow and very few moving 
parts.  They are characterized by extremely durable pumping mechanisms.  
Many of the devices are seeking approval for DT.  
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Figure 4:  The HeartWare ® HVAD (left) and the internal centrifugal rotor (right) [32] 
In this study, the HeartWare® HVAD, a centrifugal continuous flow device, 
is being utilized as the experimental MCS device.  Depicted in Figure 4 (left), it is 
considered a fourth generation VAD because of its small size (<150g) and the 
fact that it can be implanted above the diaphragm. The device received BTT FDA 
approval in 2012 for patients with end-stage heart failure. The pump is the first 
FDA approved full-support device -- it has the ability to produce up to 10L/min 
flow -- to be implantable in the pericardial space.  The centrifugal rotor, shown in 
Figure 4 (right), is the device’s only moving part.  It is magnetically suspended 
and designed to maximize device durability.  Globally, the HVAD has been 
implanted in more than 2,500 heart failure patients[33].  
1 
2 
3 
D. Myocardial Recovery 
1 
2 
Although mechanical circulatory support has been increasingly reliable in 
treating and sustaining patients with end-stage heart failure, many questions 
have been raised about the possibilities of recovery.  With increasing VAD 
miniaturization, durability, and adaptability, patients have been reported to have 
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undergone heart failure recovery.  The unloading of the ventricles not only 
alleviates the symptoms of heart failure, but it has also been shown to reverse 
heart failure as the ventricles undergo reverse-remodeling.  VAD support, 
allowing for hemodynamic unloading, been shown to trigger neuro-hormonal, 
cellular, and tissue adaptations towards the less pathologic state[34].  These 
adaptations imply great myocardial plasticity and the ability for the heart to heal.  
These findings also reveal that mechanical overload is the primary factor 
in sustaining the state of heart failure.  With complete cardiac unloading, the left 
ventricle shows an almost immediate decrease in end-diastolic volume and an 
increase in wall thickness[35].  As this hemodynamic change is sustained, the 
body shows a gradual decrease in pathologic neuro-hormonal activation[36].  
Mechanically unloading the heart encourages a decrease in myocyte 
hypertrophy[37], increased systolic contractility, improved diastolic relaxation[38], 
a restoration of normal electrical activity[39], and decreased tissue fibrosis[40].  
With these findings in mind, MSC is not only being used to support refractory 
patients, but is also being researched as a bridge to recovery device.  
Researchers are creating a new MCS treatment paradigm that includes 
mechanical rest and restoration. The heart is immediately unloaded for a period 
of myocardial rest and is allowed to return to its normal un-dilated state.  It is then 
gradually be reloaded for a period of functional restoration therapy.  The 
myocardial tissue is slowly reloaded and trained to sustain a normal cardiac 
output. In this study, the HVADs will be used for full-support and complete 
unloading, followed by a partial support restoration period. 
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E. Regenerative Medicine 
1 
2 
Because of the possibilities of heart failure recovery and recent 
advancement in tissue engineering, many researchers have focused on cellular 
therapy and on the use of biomaterials to aid in heart failure recovery.  Several 
strategies for the treatment of myocardial infarction and heart failure using 
biomaterials are depicted in Figure 5. 
 
Figure 5:  Biomaterial strategies for treatment of myocardial infarction. (a) polymer mesh 
restraints to prevent remodeling, (b) implantable scaffold seeded with cardiomyocytes in vitro, (e) 
injectable scaffold as a delivery vehicle for cells, (d) injectable decellularized scaffold, (e) 
injectable scaffold with therapeutic agents [41] 
Researchers have developed implantable polymer meshes, Figure 5 Part 
(a), that act as a restraint on the expansion of the heart.  It has been shown that 
restraining the initial infarct expansion process prevents a progressive decline in 
cardiac function.  A polymer mesh, sutured exclusively onto the area of infarct, 
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helped to preserve LV geometry and to reduce instances of mitral 
regurgitation[42]. However, it was shown that wrapping the entire LV helped to 
preserve normal LV volume[43].  Cardiac support devices, which wrap both 
ventricles, have been shown to decrease end diastolic LV volume, myocyte 
hypertrophy, and fibrosis[44].  Polymer mesh restraints have shown promising 
results in animal studies, but initial results in the clinic have been conflicted.  
Researchers are also pursuing other biomaterial strategies, such as cellular and 
scaffold implantation to aid in tissue regeneration. 
Researchers have studied cellular transplantation as a means of cardiac 
repair.  Some of the first studies involved direct injection of viable cells to the 
infarcted tissue, or cellular cardiomyoplasty[41].  However, this technique is 
limited by poor cellular retention and transplant survival[45].  With the 
development of new biomaterials and tissue engineering, more recent studies 
have attempted to create in-vitro engineered tissue, Figure 5 Part (b).  The tissue 
is often composed of a scaffold seeded with a cell type, via in vitro culturing, 
which is implanted into the myocardium. 
Much research also is focused on the usage of decellularized biological 
scaffolds in the treatment of damaged and necrotic tissue, Figure 5 Part (d).  
These applications include esophageal and muscle reconstruction[46], aortic 
grafts[47], tendon rupture[48], intestinal mucosa defects[49], skin grafts[50], and 
now myocardium[51].  In these applications, the scaffolds are composed of 
naturally occurring extracellular matrix (ECM) derived from a xenogenic tissue 
source, such as porcine intestinal submucosa.  The biologic ECM scaffolds 
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contain the same structural and functional proteins that are present in the native 
ECM and are responsive to the same ECM proteases[48].  This means that the 
scaffolds are easily degraded, infiltrated, and incorporated into new tissue by the 
native cells in a matter of 60-90 days[52].  It is hypothesized that ECM 
degradation and remodeling cause progenitor cell recruitment and bioactive 
molecule release, such as the release of growth factor, which is responsible for 
the construction of remodeled tissue[48]. The ECM scaffold has been shown to 
encourage tissue vascularization because of progenitor cell release of vascular 
endothelial cell growth factor[53].  The reconstruction of a normal ECM is 
important in the myocardial healing process because it provides a healthy cellular 
microenvironment that supports cellular migration, growth, differentiation, and 
signaling[54].   
Many such biological scaffolds are created as sheets or patches, which 
are then sutured onto an infarcted area.  In one study, a myocardial patch was 
shown to be populated with small regions of myocytes within 8 weeks of 
implantation[51]. In more recent studies, the sheet of ECM is broken down into 
an injectable emulsion. This process breaks down the relatively large patch into 
much smaller and more manageable micro-scaffolds that can be directly injected 
throughout the infarcted tissue rather than placed at the surface. Although the 
emulsion is fine enough to be injected as a therapeutic gel, the scaffold pieces 
remain comparatively large at the cellular level and provide matrix 
microenvironments for progenitor cell invasion and new tissue deposition[55].  It 
has been shown that ECM injections improved myocardial healing with LV wall 
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thickening and a preservation of cardiac systolic function[55].  In this study, an 
ECM emulsion (CorMatrix® Roswell, GA) will be used in combination with MCS 
to determine the benefit of the combination of therapies: ventricular unloading 
and biological scaffold support for healing. 
1 
2 
3 
F.  Heart Failure Models 
1 
2 
In order to accurately test possible heart failure therapies in the pre-clinical 
setting, relevant models of the disease must be utilized, which means conducting 
tests on a large animal model, closely related to human cardiovascular anatomy 
and physiology.  The industry standard model for MCS safety, reliability, and 
efficacy testing is healthy calves, as they are large enough to accommodate such 
devices.  However, there are very few large animal heart failure models utilized 
today.  Having an accurate model of the heart failure disease is extremely 
important for testing the physiological response to heart failure, treatment, and 
recovery for both MCS and tissue engineering applications.  An accurate animal 
model is important in examining the mechanisms and pathways of myocardial 
remodeling[56] and heart failure recovery during therapy[57, 58]. 
Previously, researchers have developed non-ischemic large animal heart 
failure models that utilize toxic coronary infusions of doxorubicin to induce 
myocardial necrosis[59]. However, non-ischemic heart failure only accounts for a 
third of heart failure patients.  Because ischemic heart failure is the more 
prevalent type of heart failure in humans, this study uses a novel bovine chronic 
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ischemic heart failure model.  This model was first described in a previous 
manuscript[1], in which the left coronary artery is selectively embolized using 
90μm polystyrene microspheres.  This procedure produces a region of 
myocardial infarction within the wall of the LV with acute ischemic insult.  The 
heart failure pathology is allowed to develop for a minimum of 30 days, and the 
damage, such as ventricular remodeling and hemodynamic changes, is 
assessed using several analysis techniques including weight monitoring, 
imaging, hemodynamic biosensing, and regional blood flow analysis. 
1 
2 
3 
G. Project Aim 
1 
2 
The overall objective of the study is to demonstrate the efficacy of a new 
heart failure treatment paradigm that combines the regenerative aspects of 
extracellular matrix therapy and the rehabilitative aspects of mechanical 
circulatory support.  The hypothesis is that the combination of both therapies will 
demonstrate a better treatment strategy than each individual therapy.  The 
rationale is that the MCS device will provide unloading and support myocardial 
reverse remodeling, while the ECM therapy will encourage the regeneration of 
healthy myocardial tissue. 
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II. ANALYTICAL TOOLS 
1 
2 
3 
A. Weight and Body Condition Score 
1 
2 
Body weight and condition are very important indicators of health. An 
average healthy Jersey calf is expected to grow approximately 20 kg a month 
(0.6 kg/day) within the first 3–7 months[60], which is the ideal timeline for heart 
failure treatment studies.  Deviations from this growth rate can help to confirm 
heart failure pathology and suggest recovery with treatment.  Changes in weight 
are an indicator of cardiac cachexia, or body wasting.  Cachexia is characterized 
by a loss of lean tissue, fat tissue, and bone tissue, and is thought to be 
governed by a neurohormonal response to heart failure[61].   
The body condition score (BCS) is an indicator of the amount of stored 
energy reserves and good health. The score is judged on the amount of fatty 
tissue distributed throughout the animal. A drop in BCS could indicate severe 
heart failure pathology.  
1 
2 
3 
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B. Blood Specimens 
1 
2 
Complete blood count (CBC) is a laboratory test for measuring the number 
of red blood cells, white blood cells, and platelets as well as amount of 
hemoglobin and hematocrit percentage in a subject’s blood.  CBC can be used to 
diagnose infections, blood clotting problems, and anemia[62].  With the HVAD 
implant and external driveline, it is vital to test for and immediately treat 
infections.  When using a mechanical circulatory support device, it is also 
important to test for plasma-free hemoglobin, an indicator of hemolysis, or 
destruction of red blood cells.  In normal and healthy conditions, there should be 
no detectable plasma-free hemoglobin.  A positive result is an indicator of blood 
trauma associated with MCS and surgery.  A troponin test is used to test for 
levels of troponin T and troponin I in circulation, which are released with 
myocardial damage.  The amount of troponin in the blood is proportional to the 
amount of damage. 
1 
2 
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C. Imaging 
1 
2 
Cardiac imaging is a vital tool in the diagnosis and analysis of heart 
failure.  Physicians use imaging to diagnose several types of structural damage 
seen in heart failure patients, such as cardiomegaly (enlarged heart) and systolic 
dysfunction.  Echocardiogram (ECHO) is one of the most common noninvasive 
cardio-imaging techniques.  Using ultrasound technology, cardiac function can be 
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assessed including systolic and diastolic LV volumes and ejection fraction. 
ECHO can be used to diagnose mitral regurgitation and aortic insufficiency.   
Fluoroscopy is another useful, but more invasive, imaging technique.  
Through the use of X-ray and radio opaque dye, coronary anatomy and blood 
flow can be visualized.  Figure 6 is an example fluoroscopy image showing a still 
frame of an LV gram in the left panel and the isolated left main coronary arteries 
in the right panel.   
  
Figure 6:  Pre-embolization fluoroscopy image of (left) left ventricle and aorta and (right) left main 
coronary arteries 
1 
2 
3 
D. Hemodynamics 
1 
2 
Altered hemodynamics is a major factor in cardiovascular disease and 
heart failure. Hemodynamics can be measured to understand the underlying 
mechanical processes associated with ventricle dilation and systolic dysfunction.  
left ventricle pressure (LVP), aortic pressure (AoP), arterial pressure (ART), 
central venous pressure (CVP), left ventricular volume (LVVol), and 
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electrocardiogram (ECG) waveforms are collected and analyzed to reveal 
different disease states. During a myocardial insult, such as the coronary 
embolization used in this study, immediate changes in the electrocardio-activity, 
such as an elevation in the ST segments, occur as portrayed in Figure 7.  ST 
elevation is an indicator of cardiac muscle damage as the contractile and 
electrical properties of the heart, such as neuromuscular repolarization pathways, 
change. Also depicted in Figure 7 are noticeable changes in the aortic and LV 
pressures during the progression of heart failure.  Not only do peak systolic 
pressures drop, there are also changes in ventricle relaxation and filling during 
diastole.  While in the normal state, the ventricle is fully relaxed for a significant 
fraction of the cycle, creating almost binary pressure conditions.  The heart is 
instantaneously fully relaxed or contracted.  In the heart failure state with diastolic 
dysfunction, the contraction and relaxation states are not as starkly defined.  At 
the end of diastole, the low pressures of diastole gradually waver up into the high 
pressures of systole. 
 
Figure 7:  Hemodynamic changes during coronary embolization:  (top) aortic pressure (bold line) 
and left ventricular pressure (dotted line), (bottom) ECG; (left) normal state, (middle) post 
embolization, and (right) chronic heart failure conditions 
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Hemodynamic waveforms can be used to visualize and assess ventricular 
unloading during treatment with mechanical circulatory support.  Figure 8 shows 
the reduction in LV pressures as the continuous flow VAD unloads volume from 
the ventricle.  As the pump speed is increased from partial to full support, LVP is 
minimized along with the pulsitility of AoP.  At complete unloading, the aortic 
valve is completely bypassed and remains closed. 
 
Figure 8:  Hemodynamic changes associated with ventricular unloading 
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E. Regional Blood Flow Calculations 
1 
2 
The measurement of regional blood flow (RBF) is extremely important for 
understanding cardiovascular efficacy and function, since the definitive target of 
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cardiac function is end organ perfusion.  Microspheres have been used to study 
RBF for over 40 years[63].  Traditionally, microspheres were radioactively 
labeled, but this method had distinct disadvantages due to health and 
environmental hazards and relatively short radioactive isotope half-lives[64]. This 
made chronic experiments particularly difficult and costly.  Fluorescently labeled 
microspheres (FM) are the ideal alternative, since they eliminate the 
disadvantages associated with radioactivity.  FM do not have fluorescent half-
lives, making chronic studies possible. Multiple colors of FM can be used in each 
subject to compare different experimental conditions or time points [65].   
Microsphere distribution is used to accurately estimate regional blood flow 
depending on several assumptions.  Upon injection into the arterial system, the 
microspheres must be well mixed and evenly distributed in the blood.  That 
ensures that the concentration of microspheres is consistent at every arterial 
branch and that each organ receives a consistent dose of microspheres 
according to the organ’s perfusion[66].  In order to ensure optimum mixing for the 
study of systemic flow, the initial injection must take place the farthest up-stream 
from the target organs.  It has been shown that injection into the left atrium or LV 
allows for accurate systemic measurements[67]. Next, the entire dose of 
microspheres must be entrapped in the vascular bedding during the first 
circulation and remain entrapped until tissue recovery[66].  This ensures that 
microspheres are not recirculated to certain tissues, skewing the original pattern 
of blood flow.  Lastly, the entrapment of microspheres must not occlude vessels 
or affect the hemodynamics of organ blood flow[66]. To address these 
26 
 
constraints, the size of the microsphere is carefully considered, as the size of 
capillaries and arterial anastomosis may vary between species and organ[68].  
The microspheres must be large enough to ensure that a significant number of 
them do not pass into venous circulation.  On the other hand, the microspheres 
must be small enough to embed in only the smallest diameter capillary beds 
without occluding major vessels and changing the native pattern of blood flow. 
At each time of FM injection, a reference blood sample is taken at a 
known rate of withdrawal.  This blood sample is used in the final RBF calculation.  
In order to quantify the amount of FM in each sample, the microspheres are 
extracted from the tissue and analyzed through flow cytometery.  A specific 
amount of control FM are added to each sample. The remaining microspheres 
can be quantified in relation to the control.  A fluorescent dot plot is created, 
separating the FM into regions according to the intensity of red and yellow in 
each FM color as shown in Figure 9.  The clusters are then isolated into elliptical 
regions-of-interest and counted. 
 
Figure 9:  Example fluorescent microsphere dot plot [69] 
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RBF is calculated based on the ratio of microspheres per gram of tissue to 
the amount of microspheres per reference blood sample according to the 
following equation: 
     (
  
  
) 
Where Qi is the regional blood flow per gram (ml min
-1 g-1) of the sample, Ci is the 
microsphere count per gram of tissue in the sample, Qr is the reference blood 
sample withdrawal rate (ml min-1), and Cr is the microsphere count in the 
reference blood sample[69].  Once Qi is calculated, it can be used to investigate 
RBF and end-organ perfusion for the different states of heart failure, heart failure 
recovery, and even HVAD motor settings. 
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F. BrdU Cellular Proliferation Assay 
1 
2 
5-bromo-2’-deoxyuridine (BrdU) is a synthetic nucleoside, uridine 
derivative, used in the detection of proliferating cells in live tissue.  Researchers 
first developed it as a way to determine the proliferative index of certain 
tumors[70] without the use of hazardous radiolabeled substrates and time 
consuming methods, such as [3H]-thymidine autoradiography[71].  BrdU usage is 
also advantageous because it allows for the detection of labeled cells in relatively 
thick tissue samples[72].  It can be used in both cell culture and living tissue 
applications.  BrdU can be administered to animals either shortly before 
euthanasia or as a chronic treatment.  Because of these advantages, BrdU is 
used widely in neurogenesis and myogenesis studies.   
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Cardiomyogenesis is a controversial topic in biomedical research.  In the 
field of cardiovascular research, it is deeply engrained that the heart is a 
postmitotic organ. The number of parenchymal cells is established at birth, and 
cardiomyocytes cannot be replaced when lost to cardiovascular disease[73]. 
However, with the discovery of native cardiac stem cells in developing, postnatal, 
and adult hearts, the traditional view has been challenged and it has been 
confirmed that cardiomyocyte turnover naturally occurs[74]. The cardiovascular 
research field is increasing incorporating BrdU to study cardiomyocyte turn over 
and heart failure recovery. 
 
 Figure 10:  Structure of 5-bromo-2’-deoxyuridine (BrdU) [75] 
As an analogue of thymidine, BrdU is spontaneously incorporated into 
newly formed DNA as cells undergo the synthesis phase of the cell cycle. The 
chemical structure of BrdU is depicted in Figure 10.  BrdU is detected through the 
use of immunohistochemistry.  A monoclonal antibody, directed against single-
stranded DNA containing BrdU, is added to the sample[76].  In order to bind to 
the DNA, it must first be denatured into the single-stranded form.  This may 
involve treatment with HCl or with DNase 1[77]. A secondary antibody, labeled 
with a specific marker, is added and it binds to the original antibody.  The sample 
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is then imaged and BrdU positive cells are counted.  A secondary label can also 
be used to isolate a specific cell type or cellular component, such as the nucleus, 
within the tissue sample.  
One disadvantage of BrdU labeling is that it only labels cells at a specific 
time point in the cell cycle, during the synthesis of DNA.  In order to fully label 
cells that are actively proliferating, BrdU must be administered multiple times 
throughout the desired period of study[78]. The literature suggests that BrdU is 
available for DNA incorporation for only a few hours after administration[71]. The 
half-life of BrdU is extremely short (2 hours), since it is rapidly metabolized by 
dehalogenationin in the plasma[79]. The body quickly eliminates it. Even with 
multiple injections at dosages of 25-100mg/kg of body weight, BrdU may only 
label a portion (60%) of the proliferating cellular population[80].  
  
Figure 11:  BrdU labeled human myocardium comparing the difference between partial BrdU 
labeling in cases of cells undergoing DNA repair and full incorporation of BrdU in proliferating 
cells (arrow) [74] 
 
Another important consideration in labeling DNA synthesis as a marker for 
cellular proliferation is that mature cells often undergo DNA repair.  DNA repair is 
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performed by cellular enzymes in order to ensure genomic stability[81]. However, 
DNA repair occurs at only discrete sites and is labeled in a punctuated pattern.  
These myocyte nuclei can be distinguished from nuclei undergoing DNA 
synthesis because the BrdU is incorporated evenly across the entire strand. 
Figure 11 demonstrates the difference between punctuated incorporation of BrdU 
in myocyte undergoing DNA repair (white box) and total incorporation of BrdU in 
proliferating myocyte (white box with arrow). 
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G. Histopathology 
1 
2 
Histopathology is an important tool in determining disease states on the 
cellular level.  It involves the examination of tissue specimens, using microscopy, 
by a medically qualified pathologist.  The tissue is fixed, sectioned, and stained to 
visualize cellular components. The pathologist is able to identify certain indicators 
of disease, in the case of myocardial infarction: necrosis of myocardiocytes, 
cellular granulation, and collagen deposition.  The amount of scar tissue and 
fibrosis is able to be quantified as an indicator of myocardial damage[82]. 
1 
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III. METHODS  
1 
2 
3 
A. Experimental Design 
1 
2 
Figure 12 shows the project organization for the ECM and MCS study, 
outlining the experimental groups, measurements, and timeline.  This project 
presents the results for the 60-day group, with the goal of producing preliminary 
data that demonstrates the efficacy of combination ECM and MCS therapy.  
 
Figure 12:  Experimental design to investigate the efficacy of ECM (CorMartix®), HVAD 
(Heartware®), and HVAD+ECM to promote myocardial remodeling and recovery 
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Male jersey calves (n=2) were used in each experimental group. The 
animals had a desired initial weight of 75±10kg. The animals were quarantined 
for a minimum of 14 days, given prophylactic antibiotic treatments, and were 
inspected by the veterinarian faculty.  Once out of quarantine, each animal 
underwent a coronary embolization procedure in order to produce a model of LV 
failure.  The heart failure pathology was allowed to develop over 30–60 days to 
produce chronic ischemic heart failure conditions.   
Due to the small sample size, the 6 animals were then semi-randomly 
divided into 3 study groups based on severity of heart failure.  The average heart 
failure ejection fraction was kept relatively similar across each group.  Each 
group received one heart failure treatment method:  HVAD only, ECM only, and 
combination HVAD+ECM.  An animal terminal study was performed 60 days after 
each treatment and the animal was euthanized accordingly.  The animals were 
handled in accordance with the National Institutes of Health, and all experimental 
procedures were approved by the University of Louisville Institutional Animal 
Care and Usage Committee (IACUC). 
1 
2 
3 
B. Surgical Procedures 
1 
2 
 Throughout the study, the animal underwent a total of 3 different surgical 
procedures:  1) heart failure induction via coronary embolization, 2) treatment 
initiation (ECM injection, HVAD implant, and combination HVAD+ECM), and 3) 
terminal study.  
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1. General Surgical Preparations 
In each of the aforementioned surgical procedures, the following practices 
were consistently used.  On the day prior to surgery, a Fentanyl 25 or 50 µg/hr 
transdermal patch was applied to the animal’s flank in order to decrease overall 
pain.  The animal was weighed to obtain its normal weight.  The animal was then 
fasted 18–22 hours before surgery.  Water was withheld for a minimum of 12 
hours before surgery.  
On the day of surgery, the calf was weighed to obtain the reduced NPO 
(nothing-by-mouth) weight.  An intravenous catheter was placed in a marginal 
ear vein.  For embolization procedures, anesthesia was induced via intravenous 
administration of Valium and Ketamine.  For treatment and end study 
procedures, Propofol was used.  Once lightly anesthetized, the calf was 
intubated and anesthesia was maintained via Isoflurane (3–5%) with oxygen 
saturation maintained above 90%.  
In the operating room, strict aseptic technique was used for all surgical 
procedures, with exception of the terminal study procedure.  The animal was 
administered Cefazolin (prophylactic) and Fluxinin Maglumine (analgesic).  ECG 
clips and a pulse oximeter were attached for intra-operative monitoring.  
Magnesium and heparin were given via intravenous infusion to support cardiac 
function and prevent coagulation.  In order to monitor arterial pressure (ART) and 
central venous pressures (CVP), temporary partially-veloured catheters were 
placed in the carotid artery and jugular vein and secured to the skin.  Once 
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patency was achieved, the catheter was connected to a pressure transducer line 
for pressure monitoring.  
2. Coronary Embolization 
Prophylactic Atenolol (beta blocker) was given 12 hours prior to surgery in 
order to decrease embolization mortality.  In the fluoroscopy operating room, the 
calf was placed in a lateral recumbency position.  An AccessTM Vascular Access 
Port (VAP) was implanted prior to embolization.  The VAP catheter was inserted 
into the jugular vein opposite to the CVP line, and the remaining length was 
tunneled under the skin toward a second incision near the topline of the neck.  
The access port was then connected to the catheter, the patency was checked, 
and then it was locked with TCS solution.  Additional heparin was given to 
prevent coagulation, and a Cordis sheath was placed into the carotid artery using 
a modified Seldinger technique.  A unit of Lidocane was given and Amiodarone 
drips were started to prevent arrhythmias.   
Coronary embolization was achieved by injecting polystyrene beads into 
coronary circulation.  The embolization solution consisted of polystyrene beads 
(Polybead® Polystyrene 90.0 μm microspheres, 2.64% Solids-Latex, 
Polysciences, Warrington, PA), bacteriostatic saline, and radio-opaque dye 
(Conray 43, Iothalamate Megumine 43%, Mallinckrodt Inc., St. Louis, MO) in a 
2:1:1 ratio.  A target dose of the mixed embolization solution was calculated per 
animal (0.17 mL solution/kg normal calf weight).  A J coronary catheter was 
positioned in the left main coronary artery and position was confirmed by 
coronary angiography with radio-opaque dye.  A preconditioning dose of 
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microsphere solution (3ml) was administered into the left main coronary artery.  
The animal was then monitored over the course of 20 minutes.   
Using the calculated target dose as a guide, the remaining volume of 
microsphere solution was given in alternating doses (1–3ml) between the left 
anterior descending and circumflex coronary artery, allowing for a minimum of 10 
minutes between each dose.  The actual dosage used was adjusted based on 
the animal’s response to each injection.  The animal was monitored for severe 
and sustained electrocardiographic changes (ST segment changes) and 
impaired cardiac function (assessed via echocardiogram).  The embolization was 
considered successful with a minimum of a 1mV ST change and a sustained 40–
50% decrease in ejection fraction (EF).   Upon completion of the embolization 
procedure, the actual volume of administered microsphere solution was 
recorded.   
60 minutes after the initial embolization preconditioning dose, a bolus of 
Furosemide was administered to promote diuresis, mitigate pulmonary effects 
associated with elevated LV filling pressures involved in heart failure, and 
promote post-operative recovery and survival.  The cordis sheath was removed 
and the incision was closed.   The animal was then allowed to recover in post-op 
care. 
3. Heart Failure Therapy Initiation Procedures 
Once the animal had sustained symptomatic heart failure (lowered EF) for 
approximately 60 days, a treatment (HVAD, ECM, or HVAD+ECM) could be 
initiated. The same general surgical procedures were used for animal 
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preparation, anesthesia induction, and patient monitoring.  In the operating room, 
the animal was positioned in a right lateral recumbency position.  A thoracotomy 
was performed.  Succinylcholine (neuromuscular blocking agent) and heparin 
were administered prior to chest incision.  A 14cm incision was made, and the 5th 
rib was removed.  The heart was exposed and pericardium was opened to allow 
for each heart failure treatment procedure.  
After the treatment was complete, the pericardium was closed.  A chest 
tube was inserted into the pericardial space and secured.  Bupivacaine and 
epinephrine was injected into the intercostal margins to reduce post-operative 
pain.  The chest incision was closed and the animal was moved to post-op 
recovery for monitoring and pharmaceutical treatment. 
a. HVAD Implant.    Mechanical circulatory support was achieved through 
implantation of the clinically-used HVAD (HeartWare, Miami Lakes, FL).  The 
HVAD device was prepared by assembling the graft outlet and bend relief rings.  
The pump was then filled with saline and its motor was initially run for a minimum 
of 5 minutes to ensure proper function.  The HVAD driveline was tunneled under 
the skin to the dorsal aspect next to the spine.  Heparin (10,000 units) was 
administered to maintain the desired ACT (>480 seconds), which prevented 
coagulation during device implantation.  The HVAD graft was cut to proper 
length. The aorta was clamped and the graft was anastomosed to the aorta.  
The apex of the heart was elevated and a sewing ring was sutured, 
circumferentially, to the apex.  Using a scalpel, the tip of the apex was removed 
and an incision was cut into it for insertion of the coring device.  The coring 
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device was used to create a circular hole within the sewing ring at the apex of the 
heart.  The inlet of HVAD device was then inserted through the sewing ring and 
secured.  The HVAD was activated and the motor speed was initially adjusted to 
achieve maximum heart unloading.  That involved a complete unloading of LV 
pressure to allow the cardiac muscle to “rest” and the dilated LV volume to return 
to more normal values.  Complete unloading was assessed by the following 
parameters: sustained closure of aortic valve, absence of mitral regurgitation, 
and septum return to midline.  
Once the device implantation was complete, the incision was closed and 
the HVAD driveline was secured to the skin.  In post-op recovery, the pump 
speed was maintained and adjusted throughout the 60-day treatment.   Around 
day 40, the HVAD speed was reduced by 30% in order to initiate a weaning 
process.  By day 50, the pump speed was reduced by 75% in order to restore 
optimal cardiac function.  
  
b. ECM Injection.  The ECM therapy was achieved by injection of a 
proprietary ECM emulsion (CorMatrix® Cardiovascular, Inc, Roswell, GA) into the 
infarcted regions of the LV.  Prior to ECM injection, the aorta was temporarily 
clamped as if preparing for graft anastomosis.  This mimics the HVAD 
implantation protocol as a control.  The infarcted areas of the left ventricle were 
identified and a 3x3 matrix was drawn covering a selected region.  An 
echocardiogram (ECHO) at each matrix square (approximately 1 in²) was taken 
using a small surgical ECHO probe on the surface of the heart.  LV wall 
thickness was measured at each square to determine the depth safety limit for 
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the ECM injections to prevent ECM from entering the LV chamber and potentially 
acting as emboli.  The ECM emulsion was then injected into the LV muscle 
(1mL/square) using a pneumatically driven injection device (CorMatrix® 
Cardiovascular, Inc, Roswell, GA)  at each matrix square as shown in Figure 13.  
 
Figure 13:  Photograph of CorMatrix® ECM injection into an infarcted region of the left ventricle 
An echocardiogram was then retaken at each square to visualize the 
injected ECM collagen spots.  Additional injections were performed if the ECM 
spot density was minimal.  Suture was used to outline the corners of the injected 
area for reference during necropsy.  Once the procedure was complete, the 
incision was closed and the animal was moved to post-op recovery. 
c. HVAD+ECM Combination Procedure.  The combination therapy 
procedure follows both the previous HVAD implant and ECM injection 
procedures.  The ECM injections were performed first.  Once the ECM injections 
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were complete and animal’s conditions stabilized, the HVAD implant procedure 
took place, starting with HVAD preparation and graft anastomosis.  Once the 
HVAD was implanted, the chest incision was closed and the animal was moved 
to post-op recovery. 
4. Pharmacological Treatment Techniques  
During each of the surgical procedures, close attention was paid to 
cardiac function and animal stability.  The following drugs and fluids were used to 
provide intraoperative support: 
1. Antiarrhythmics:   
a. Amiodarone (1.8mg/ml) 17-25ml/hr 
b. Lidocaine (100mg boluses) 
2. Inotrope infusions 
a. Phenylepinephrine (100mg/ml) 1-6ml/hr 
b. Dobutamine (0.5mg/ml) 1-6ml/hr  
c. Epinephrine (25mg/ml) 1-2ml/hr  
1. Lactated Ringers Solution 
3. Vitamin B Complex Solution 
4. Magnesium Sulfate infusion (2g)  
5. KCl (2mEq/ml) 5ml/hr  
During post-operative care, the animal was monitored 24 hours a day by 
trained attendants.  Animal care was overseen by a Dr. of Veterinary Medicine.  
Post-operative and treatment care involved monitoring for arrhythmias and 
managing blood pressure.  Care attendants also treated the animals for several 
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conditions associated with HF and cardiothoracic surgery.  The following fluids 
and pharmacological agents were used in post-operative care to provide support 
to the animal.   
1. Antiarrhythmics 
a. Amiodarone (1.8mg/ml) 17-25ml/hr  
b. Lidocane (1 amp boluses) 
2. Inotrope infusions 
a. Phenylepinephrine (100mg/ml) 1-6ml/hr 
b. Dobutamine (0.5mg/ml) 1-6ml/hr  
3. Vasodilator (Nitropress) – maintain a mean arterial pressure of 60-80 
mmHg 
4. Beta blocker (Atenolol) – maintain a resting heart rate below 100 bpm. 
5. Diuretic (Furosemide) – prevent pulmonary edema and prevent right heart 
failure. 
6. Lactate Ringer Solution – maintain fluid volume and IV drip medication 
carrier. 
7. Antibiotics 
a. Cefazolin  
b. BioMycin  
8. Probios® – prevent rumen dysbiosis  
Depending on the severity of the animal’s condition, the arterial and 
venous lines were maintained for 7–10 days, which allowed for constant arterial 
and venous pressure monitoring.  The lines were removed once the animal no 
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longer required IV drips and medication.  The venous access port (VAP) was 
maintained throughout the duration of the study.  Arterial blood gases and 
electrolytes were continuously monitored throughout the study to screen for 
abnormalities and to guide pharmaceutical care. 
5. Necropsy/Euthanasia 
After the 60-day course of treatment was complete, a terminal study was 
performed.  The procedure was consistent with recommended practices of the 
2007 American Veterinary Medical Association Guidelines on Euthanasia and 
involved minimal distress to the animal.  The animal was prepared for surgery in 
the usual method.  It was placed in a lateral recumbancy position.  30,000 units 
of heparin were given to maintain a high ACT (>480 seconds) to prevent 
coagulation during the procedure.  A cordis sheath was placed into the carotid 
artery.  End study measurements were taken including: Echocardiogram 
(ECHO), LV Gram, Hemodynamics, and Fluorescent Microsphere circulation 
studies.   An in-depth description of each technique is discussed in Part C: 
Analytical Techniques. 
Upon completion of the end-study procedure, the calf was euthanized 
with an IV bolus of Beuthanasia.  The animal was then exsanguinated.  The 
veterinarian completed a gross examination.  Complete photographic 
documentation of the procedure was performed, and tissue samples from all 
major end-organs and multiple regions of the heart were collected for RBF, BrdU 
assay, and histopathology.  If present, the HVAD was retrieved. 
1 
2 
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3 
C. Analytical Techniques 
1 
2 
1. Clinical Evaluation 
Animal weight was measured on a weekly schedule and at important time 
points using a bovine-specific scale (SPX scale systems, GSE model 350, Novi, 
MI).  From this information, the rate of growth can be established in normal, heart 
failure, and treatment conditions.  The care attended noted the animal’s body 
condition score, or BCS, on a daily basis.   
2. Blood Specimens 
Complete Blood Count was analyzed weekly at each important time point 
using HEMAVET 950 (Drew-Scientific, Oxford, CT).  Troponin was tested at 
baseline and 72 hours post embolization.   Plasma free hemoglobin was 
analyzed at heart failure condition baseline and weekly after initiation of 
treatment.  Both blood tests were analyzed by a CLEA-certified laboratory 
(Jewish Hospital, Louisville, KY).   All results were recorded in the subject logs. 
3. Echocardiography 
1 
Echocardiograms (ECHO) were taken on a weekly basis throughout the 
study and during each surgical procedure and time point using a Phillips iE-33 
machine.  Transthoracic ECHOs (TTE) were taken using a S8-3 ultrasound 
probe, and transesophageal ECHOs (TEE) were taken using the X7-2t probe.  
Weekly ECHOs, performed with the animal in the awake state, were always 
taken using the TTE probe.  Once an animal was anesthetized, TEE ECHOs 
were taken to supplement the transthoracic recordings.  The TEE probe was 
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inserted into the animal’s stomach via the esophagus, and the probe tip was 
angled to obtain an apical four-chamber view of the heart.  Using either probe, a 
beat-by-beat 2-D recording was collected.  Using a modified Simpson’s 
summation technique, LV length, area, and volume at both end-systole and end-
diastole were calculated.   Using the TEE probe, a 3-D ECHO recording could be 
collected and 3-D left ventricle volumes could be calculated using a modeling 
software add-in (QLAB).  The LV is modeled as a volumetric shape once the 
reviewer identifies key land marks, including the inferior wall, lateral wall, septum, 
and apex.  Both 2-D and 3-D data was collected during surgical procedures.  
Figure 14 shows an example 2-D and 3-D TEE ECHO of the left ventricle with 
end diastolic LV volume analysis. 
  
 
Figure 14:  A comparison of the left ventricular volume analysis techniques (left) 2D TEE ECHO 
(right) 3D TEE ECHO 
Using the end-systole and end-diastole LV volumes, cardiac ejection 
fraction could be calculated.  The recordings could also be reviewed for 
instances of aortic insufficiency (AI) and mitral regurgitation (MR).  When these 
abnormalities were observed, they was recorded in the animal’s echo log along 
with the ejection fraction.   
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During the heart failure induction surgery, ECHOs were taken at baseline 
and various time points to closely monitor the progress of embolization and 
cardiac function impairment.  Typically, baseline ECHOs were taken with the 
animal awake and again after anesthesia.  A third baseline ECHO was measured 
after inotropes were initiated to support the animal during the surgical procedure. 
This third baseline condition (anesthetized and on inotropic drips) served as the 
reference for cardiac function impairment during the embolization.  The target for 
successful heart failure induction was a > 40% reduction of EF with respect to the 
last baseline EF.   
ECHO measurements were recorded after the injection of 10 mL of 
microsphere solution to review the embolization progress.  Ejection fraction was 
then titrated down to the desired point (>40% reduction) by injecting 1–3 mL at a 
time, with an ECHO measurement after each dose.  Once the heart failure 
induction criteria was achieved, a final ECHO was measured 10–15 minutes after 
the final microsphere dose to verify that EF reduction was sustained.  The final 
ECHOs were taken using both TTE and TEE probes.  
During both the treatment procedure and necropsy, when the animal was 
anesthetized and placed on cardiac supporting drugs, similar pre-surgical 
baselines and end-points were taken using the TTE and TEE probes. 2 
4. Fluoroscopy and LV Gram 
1 
Through the use of fluoroscopy (GE Innova 3100), LV Grams were taken 
at key time points during the study: pre-embolization baseline, post-embolization, 
and end-study.  Due to concerns for animal well-being, fluoroscopy was not 
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performed during the treatment procedure for the chronic heart failure and post-
treatment condition. 
During embolization and end-study surgical procedures, a pig-tail catheter 
was advanced through the cordis sheath and positioned at the base of the left 
ventricle.  The catheter was connected to an angiographic injector (Mark V Plus, 
Medrad, Warrendale, PA).  Using radio-opaque dye (Conray 43, Mallinckrodt, St. 
Louis MO) and a set injection speed of 50mL/sec, the left ventricular flow field 
and coronary circulation were visualized and recorded as the catheter was slowly 
withdrawn from the left ventricle chamber into the aortic space. 
5. Hemodynamics 
1 
Hemodynamic measurements were taken during embolization and end-
study procedures.  The following signals were recorded:   
1. Arterial Pressure (ART) - mmHg 
2. Central Venous Pressure (CVP) -mmHg 
3. Electrocardiogram (ECG) - mV 
4. Aortic Pressure (AoP) - mmHg 
5. Left Ventricle Pressure (LVP) - mmHg 
6. Left Ventricle Volume (LVVol) - mL 
ART and CVP were acquired using the monitoring system from the jugular 
vein and carotid artery catheters.  The ECG signal was also acquired from the 
patient monitoring system using the ECG clips.  AoP, LVP, and LVVol were 
acquired through the use of a 6-French dual-tip pressure-volume conductance 
catheter (Millar, Houston TX).  The conductance catheter was first opened to air 
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and zeroed.  The catheter was advanced through the cordis sheath and, using 
fluoroscopic guidance, was placed in optimum position at the base of the left 
ventricle.  The data was then acquired at a sampling frequency of 400 Hz for a 
set duration of 30 seconds at a time.  After each surgical procedure, the 
conductance catheter was calibrated for post-surgical data analysis.  The 
conductance catheter was placed in a hydrostatic pressure chamber, introduced 
to multiple pressures, and the catheter’s response (AoP and LVP) was collected.  
 
Figure 15:  Example hemodynamic waveform collection (top to bottom) AoP, CVP, LVVol, ART, 
ECG, and LVP 
During embolization, hemodynamic measurements were taken at the 
following time points: pre-embolization baseline, 2-min after the pre-conditioning 
embolization dose, 20 minutes after the pre-conditioning embolization dose, and 
post-embolization.  The conductance catheter was used at only the pre- and 
post-embolization time points.  During the end-study procedure, hemodynamics 
were measured to assess the three HF treatments.  For the ECM-only animals, a 
final 60-day hemodynamic measurement was taken.  If an HVAD was present, 
hemodynamics were taken for the following conditions: VAD off, 1800 RPM 
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(neutral flow), 2200 RPM, 2600RPM, 3200RPM, 3300RPM, 3600 RPM 
(maximum unloading), chronic support RPM with no inotropic drips, and chronic 
support with inotropic drips.12 
6. Fluorescent Microsphere 
1 
Blood flow and organ perfusion were measured using 15 μm fluorescent-
labeled polystyrene microspheres (5.25 million NuFlow Microspheres, Interactive 
Medical Technology, Irvine, CA).  The fluorescent microspheres were 
administered during the embolization and the end-study procedure.  During heart 
failure induction, a pre- and post-embolization dose of microspheres were given. 
During the end-study procedure with ECM-only calves, a final dose was given. 
During HVAD only and HVAD+ECM end-study procedures, two doses were 
given with chronic support and VAD failure settings.  Each test condition 
corresponded to a unique fluorescent color within the animal. 
The fluorescent microspheres were administered to the LV via cardiac 
catheter.  As the microspheres were injected, a reference arterial blood sample 
was withdrawn at a rate of 15mL/min for 100 seconds using a calibrated syringe 
pump (Harvard Apparatus, Holliston, MA).  The 100-second withdrawal was 
initiated, followed by a 10-second count.  At 10 seconds, the fluorescent 
microspheres were injected as a bolus, followed by a 5 mL saline flush.   At 100 
seconds, the withdrawal was terminated.   
During the animal necropsy a ~5 gram sample of each tissue was 
collected and stored at 4°C. 
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1. Heart:  aorta (distal to graft anastomosis), pulmonary artery, LV 
(2 core samples), right ventricle (RV) (1 core sample), and 
septum (1 core sample) 
2. Liver:  left lobe 
3. Spleen:  right pole 
4. Lung:  right caudal 
5. Brain:  brain stem, frontal lobe, and cerebellum 
6. Kidney:  left  
7. Small Intestines 
8. Skin:  subcutaneous layer 
9. Skeletal Muscle:  Left hind thigh 
After animal necropsy, each tissue sample was processed.  The samples 
were cut down to slightly less than 3g.  One of the LV core samples was further 
dissected into three layers:  the outermost layer closest to the pericardium (M1), 
the middle layer (M2), and the innermost layer closest to the LV chamber (M3). 
The fluorescent microspheres for the reference blood samples and all tissue 
samples were quantified using flow cytometry (IMT/Stason Laboratories, Irvine, 
CA).  Regional blood flow (mL/min/mg tissue weight) was calculated for each 
condition (microsphere color) per tissue sample, based on the ratio of spheres in 
tissue, spheres in blood reference, known blood withdraw rate, and tissue 
sample mass.  
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7. BrdU Administration 
Bromodeoxyuridine (BrdU, Sigma-Aldrich®, St. Louis, MO) was 
administered intravenously at a dosage of 5 mg/kg of normal weight at a 
concentration of 20mg BrdU/ml.  BrdU was given every other day, starting on 
treatment post-op day 15 and continuing until day 60.  At necropsy, tissue 
samples were taken from the RV, anterior left ventricle (LV ant), and lateral left 
ventricle (LV lat).  Samples were fixed in formalin, cryosectioned, and stained for 
nuclei, sarcomeric actin (SA) and BrdU.  BrdU+ cells and BrdU+/SA+ cells were 
counted in each tissue sample. 
8. Histopathology 
At necropsy, the following tissue specimens (3–6mm thickness) were 
collected and fixed in 10% formalin solution. 
1. Heart:  LV apex, aortic valve, pulmonary valve, aortic annulus, 
right atrium, left atrium, LV free wall, RV free wall, IV septum, 
papillary muscles, and pulmonary artery 
2. Liver:  left and right lobe 
3. Spleen:  left and right lobe 
4. Lung:  left and right cranial, left and right caudal, 
5. Brain:  left and right cerebrum, left and right thalamus, 
cerebellum, brain stem, 
6. Kidney:  left and right 
7. Adrenal Gland:  left and right 
8. GI:  abomasum, jejunum, colon 
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Tissue sample slides were prepared using hematoxylin and eosin (HE) 
staining (Mass Histology Service, Worcester, MA) and the percentage of fibrotic 
tissue was determined for each tissue.  The slides were examined by a board-
certified veterinary pathologist, and the major findings for each subject were 
compiled in a final report. 
1 
2 
3 
D. Analysis Methods12 
1 
2 
Using the previously reported results for the 60-day chronic heart failure 
group with aggressive medical management (n=10) as a control [1], the results 
for each treatment group are presented below.  An analysis of variance (ANOVA) 
was conducted to compare the different measurement indices between each 
treatment group to determine statistical significance (p≤0.05).  All data presented 
as mean±standard deviation. 
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2 
3 
4 
5 
6 
7 
8 
9 
10 
IV. RESULTS 
1 
2 
3 
The mortality rate of the embolization procedure for each group was an 
overall reported value of 10%, which was consistent with the previous coronary 
embolism heart failure model study[18].  Mortality during embolization was 
caused by atrial fibrillation.  Baseline troponin levels, an indicator of myocardial 
damage, were within normal range.  Following embolization, peak troponin levels 
for all animals peaked over 100ng/ml, indicating severe myocardial infarction.  
The average plasma free hemoglobin (PFHb) was around 5-6mg/dL following 
treatment for all experimental groups.  Ideally, plasma contains no PFHb, 
indicating a level of hemolysis in all of the subjects.  One HVAD+ECM animal, 
number 5088, had a peak PFHb of 30mg/dL on post-op day 40.  The other 
animals had similar levels of PFHb peaking at 20mg/dL.  
The only reportable adverse event during post-operative care was an 
incident involving animal number 5086, an ECM-only treatment subject.  On post-
op day 8 following ECM therapy, the animal chewed through the arterial line and 
lost an estimated 50-100mL of blood.  The arterial line was replaced and the 
animal did not appear to be adversely affected.  Three animals were treated for 
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bacterial infections.  One HVAD-only animal was treated for infection in 
quarantine and a recurring infection during HVAD implant.  The other HVAD-only 
animal and one ECM-only animal were treated for infection after treatment. 
1 
2 
3 
 
A. Animal Weight Analysis 
1 
2 
The animals had a reported baseline weight gain rate consistent with 
previous studies.  For all groups, the baseline rate was 0.78±0.10 kg/day and the 
heart failure rate dropped to 0.64±0.11 kg/day.  The rates for each treatment 
group are depicted in Figure 16.  The values for the control group include a 
0.75±0.3 kg/day baseline.  The values for the control (60-day chronic heart 
failure) were used to compare to the heart failure time point and the 60 day 
treatment time point. 
 
Figure 16:  Comparison of baseline, heart failure, and 60 day treatment weight gain per day 
demonstrating a reduction in weight gain in heart failure for all groups and a recovery of weight 
gain in the ECM group 
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There were no reported significant (p≤0.05) differences between treatment 
groups, time points, or interactions.  For all groups, the value of heart failure 
weight gain per day drops 17±17%.  The treatment groups had varying recovery 
of weight gain, according to Table 1. 
Table 9:  Comparison of the values of weight gain per day for the control and 
treatment groups 
(kg/day) Control ECM HVAD HVAD+ECM 
Baseline 0.75±0.3 0.76±0.13 0.82±0.07 0.76±0.14 
Heart 
Failure 
0.47±0.2 0.67±0.13 0.65±0.01 0.61±0.2 
Treatment --- 0.76±0.01 0.52±0.13 0.63±0.3 
 
The values for heart failure and 60-day treatment were normalized to 
baseline in Figure 17 to visualize any trends in decreasing or increasing weight 
gain rates.  The ECM-only group had a recovery rate of 102±16% of the 
baseline, the HVAD-only group had a further reduction of the rate to 62.7±11% of 
the baseline, and the HVAD+ECM group had a recovery rate of 83.8±12% of the 
baseline. 
 
Figure 17:  Comparison of heart failure and treatment weight gain per day normalized to baseline 
weight gain per day 
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1 
2 
3 
B. Ejection Fraction and Left Ventricular Volume 
1 
2 
 In order to maintain consistency, the ECHOs used in analysis were taken 
with the TTE ECHO probe when the animal was in the awake condition with no 
inotropic agents present. The following values were calculated using only the 2D 
volume analysis technique shown in Figure 18.  
 
Figure 18:  Example 2D TEE ECHO showing (left) end diastolic and (right) end systolic LV 
volume and ejection fraction analysis (Animal #5086, embolization) 
The ejection fraction (EF) is analyzed as an indicator of cardiac function 
and myocardial contractility.  The overall baseline EF was found to be 
74.8±6.8%. The overall heart failure EF was found to be 36.4±9.5%.  The 
ejection fractions for each treatment group are listed in Table 2. Blank values for 
standard deviation indicates that a comparable ECHO (awake/no inotropes) was 
not performed at the specific time point for an animal, leaving an n=1 for the 
treatment group timepoint. 
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Table 10:  Comparison of ejection fraction for the control and treatment groups 
Treatment Control ECM HVAD HVAD+ECM 
Baseline 72 ± 8 69 ± 2.8 80 81 
Heart 
Failure 
31 ± 8 27 ± 0 41.5 ± 7.8 45 
Treatment --- 66.5 ± 4.9 69.5 ± 2.1 75 ± 4.2 
 
 
Figure 19:  Comparison of baseline, heart failure, and 60 day treatment EF demonstrating a 
reduction in EF at heart failure for all groups and a recovery of EF for all groups excluding the no 
treatment control group 
 
 Figure 19 compares the ejection fraction at all three time points.  All 
treatment groups demonstrated a 55.3±7.8% decrease in EF.  The decrease is 
comparable to the New York Heart Association (NYHA) class-IV HF patients who 
have 40% lower EF compared to normal values (65±10%). Table 3 shows the 
normalized EF values for heart failure and treatment as compared to the 
baseline. The ECM group saw a 96.6±11.1% restoration of the baseline EF, the 
HVAD and HVAD+ECM group saw an 89% restoration of the baseline EF. 
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Table 11:  Comparison of the values of normalized EF to the baseline value for the control and 
treatment groups indicating a significant (p=0.002) decrease for heart failure, and significant 
increase with recovery with treatment for all study groups. 
Normalized EF (%)  Control ECM HVAD HVAD+ECM 
Heart Failure 43.1 39.1 ± 1.6 45 55.6 
Treatment   96.6 ± 11.1   88.8 88.9 
 
The results of the ANOVA indicated that the time point significantly 
affected the normalized ejection fraction (p = 0.002) as the 55% decrease in EF 
with heart failure was significant.  However, the interaction of treatment and time 
point was not significant.   
End diastolic (ED) and end systolic (ES)  LVVols were recorded under the 
same conditions as the EF calculations and are analyzed as indicators of LV 
remodeling and systolic and diastolic function.  Figure 20 shows both ED and ES 
LVVol for the control and treatment groups at each time point. 
 
Figure 20:  Comparison of baseline, heart failure, and 60 day treatment ED and ES LVVol 
demonstrating an increase in diastolic volume in all groups for both heart failure and treatment. 
And an increase in systolic volume at heart failure for all groups and reduction in systolic volume 
with treatment for all groups excluding the no treatment control group 
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The groups had an overall baseline ED LVVol of 103±44mL and ES LVVol 
of 26±14mL. The HF condition volumes increased to 230±64mL and 149±51mL 
respectively.  The values for each treatment group are listed in Table 4. 
Table 12:  Comparison of baseline, heart failure, and 60 day treatment ED and ES LVVol 
  Control ECM HVAD HVAD+ECM 
LVVol (mL) ED ES ED ES ED ES ED ES 
Baseline 126 ± 52 36 ± 17  115 ± 73 35 ± 19 100 20 83 16 
Heart Failure 145 ± 58 100 ± 41 260 ± 18 191 ± 12 169 ± 54  100 ± 42 292 162 
Treatment     343 ± 75 118 ±42 194 ± 20 59 ± 2.8 227 ±  110  59 ± 36 
 
It is thought that rate of overall growth will affect the size of the animal’s 
heart and therefore ventricular volume.  Because there was a large range of 
animal weights among the calves, the ventricular volume was normalized to the 
weight of the calf at the time point of measurement. These values were then 
plotted in Figure 21. 
 
Figure 21:  Comparison of baseline, heart failure, and 60 day treatment for normalized ED and 
ES LVVol demonstrating an increase in diastolic and systolic volume in all groups for heart 
failure, and a decrease in diastolic and systolic volume with treatment for all groups 
The normalized plot shows a correlation consistent with the previous 
trend.  The analysis of variance for LVVol revealed that the time point was 
significant for both ED (p = 0.029) and ES LVVol (p = 0.003), which indicates that 
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the increase in volumes during heart failure and the subsequent decrease in 
systolic volume was significant.  However, there were no significant differences 
among treatment groups.  When the volumes were normalized to calf weight, the 
time point was not significant for diastolic volume. When normalized, both the 
treatment (p = 0.035) and the time point (p = 0.001) were significant for systolic 
volume, but not the interaction of the two (p = 0.363). The normalized values for 
ED and ES LVVol are listed in Table 5.  
Table 13:  Comparison of baseline, heart failure, and 60 day treatment normalized ED and ES 
LVVol demonstrating an increase in systolic volume in all groups for heart failure and a decrease 
in systolic volume for 60 day treatment 
Normalized 
LVVol (mL/kg) 
ECM HVAD HVAD+ECM 
ED ES ED ES ED ES 
Baseline 1.66 ± 1.17 0.5 ± 0.31  1.06 0.21 1.15 0.22 
Heart Failure 2.53 ± 0.11 1.86 ± 0.09 1.63 ± 0.38 0.96 ± 0.33 2.7 1.5 
Treatment 2.03 ± 0.49 0.7 ± 0.27 1.4 ±0.02 0.43 ± 0.02 1.51 ± 0.43 0.39 ± 0.16 
1 
2 
3 
C. Hemodynamics 
1 
2 
The hemodynamic waveforms were first plotted then analyzed.  Only LVP 
and AoP sensors were calibrated, so only their values were used in post-
operative analysis.  Because hemodynamics were not recorded at the time of 
implant, the chronic heart failure time point is not included.  Post-embolization is 
used as the reference for heart failure.  In order to visualize the electrocardio- 
changes associated with each time point, sample ECGs were plotted in Figure 
22. The waveforms for animals with HVAD implants were taken at neutral HVAD 
flow settings (1800 RPM). 
 
59 
 
 
Figure 22:  (A) An example waveform with labeled landmarks and a comparison of 
electrocardiogram waveforms for (B) pre-embolization baseline, (B) post-embolization, and 60 
day treatment with (C) ECM, (D) HVAD, and (E) HVAD+ECM 
 
The sample ECG waveforms show general patterns and abnormalities in 
the electro-cardiac functioning of the heart.  Immediately after embolization, the 
animal shows tombstone patterning, or extreme ST segment elevation, and T-
wave inversion.  In all the chronic treatment ECGs, the patterns return to more 
normal shapes, but there is still evidence of dysfunction in repolarization.  The 
repolarization segment (ST) in Part E appears to be completely reversed. 
However, the patient monitor might have been recording a signal from a different 
lead. 
Next, sample LVP-AoP waveforms were plotted as an indicator of 
contractile functioning.  Sample pressure waveforms for pre- and post-
embolization and for chronic treatment are shown in Figure 23.  The waveforms 
show changes in peak pressures with embolization, chronic treatment, and the 
different support levels of the VAD.  There is also a difference in the shape of 
(B) Pre-Emb.  (C) Post-Emb. 
(D) Chronic ECM  (E) HVAD 1800RPM (F) HVAD+ECM 1800RPM 
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diastole and systole for both LVP and AoP.  Diastole and systole are less defined 
than in the baseline.  The LV contraction pressures are more gradually sloping 
than the sharp contraction of the baseline waveform.  Using the HEART v2.1 
Program (Bill Perreult ©2000), LVP and AoP were analyzed for heart rate, peak 
pressures, pulse pressure, and peak pressure changes.  The results are plotted 
in Figures 24-27.  Table 6, showing the previously reported values for the control 
study, is included as a comparison to the 60 chronic treatment groups. 
Table 14:  Hemodynamic parameters for the normal control and heart failure baseline [1] 
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Figure 23:  A comparison of LVP (red) and AoP (blue) waveforms for (A) pre-embolization 
baseline, (B) post-embolization, (C) 60 day chronic ECM treatment, 60 day chronic HVAD 
treatment at (D) neutral flow – 1800 RPM, (F) partial support – 2400 RPM, (I) maximum support – 
3600 RPM, and 60 day chronic HVAD+ECM treatment 
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Figure 24:  A comparison of LVP qualities for each time point including (A) heart rate, (B) 
Average LVP, (C) end diastolic LVP, (D) peak systolic LVP, and maximum LVP (E) positive rate 
of change, and (F) negative rate of change 
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Figure 25:  A comparison of AoP qualities for each time point including (A) average pressure, (B) 
pulse pressure, (C) systolic pressure, and (D) diastolic pressure 
In Figure 24 and Figure 25, the values for the treatment time point were 
calculated using data recorded with the HVAD set to neutral flow (1800 RPM).  
The results show an increase in ED and ES LVP, (+/-) dP/dt, ED and ES AoP, 
and AoP pulse pressure for all 60 day treatment groups in comparison to the 
heart failure control group.  The ECM only group had the greatest average and 
ES LVP and ED and ES AoP and the HVAD only group had the largest (+/-) 
dP/dt at the treatment time point.  In the following figures, Figure 26 and Figure 
27, the qualities of LVP and AoP were plotted with respect to HVAD motor speed 
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to determine the effects that MCS has on hemodynamics.  These figures include 
the HVAD and HVAD+ECM 60 day chronic treatment groups. 
 
Figure 26:  A comparison of LVP qualities for varying motor speed including (A) heart rate, (B) 
Average LVP, (C) end diastolic LVP, (D) peak systolic LVP, and maximum LVP (E) positive rate 
of change, and (F) negative rate of change 
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Figure 27:  A comparison of LVP qualities for varying motor speed including (A) average 
pressure, (B) pulse pressure, (C) systolic pressure, and (D) diastolic pressure 
The HVAD+ECM group had a larger heart rate than the HVAD only group.  
Increased VAD support  increased peak systolic LVP for the HVAD+ECM 
treatment group, reduced end diastolic LVP for both groups, and did not affect 
average LVP for both groups.  Increased HVAD support increased AoP and 
reduced pulse pressure for both groups.   
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D. Regional Blood Flow 
1 
2 
Regional flood flow in each tissue sample was calculated according to the 
previous equation.  Because of low yield, possibility the result of a bad 
microsphere lot or photo bleaching, one data set was omitted for HVAD only at 
post-embolization. Data for each time point are plotted in Figure 28 and 29. The 
error bars may be truncated in order for visualization of the low perfusion tissue 
types. Figure 30, is representative of the 60 day heart failure control group. 
 
Figure 28:  A comparison of regional blood flow in each tissue type for ECM, HVAD, and 
HVAD+ECM experimental treatment groups at baseline (pre-embolization) conditions 
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Figure 29:  A comparison of regional blood flow in each tissue type for ECM, HVAD, and 
HVAD+ECM experimental treatment groups at (A) post-embolization (HVAD: n=1) and (B) 60 day 
chronic treatment 
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Figure 30:  A comparison of regional blood flow in normal conditions and in 60 day chronic heart 
failure conditions [18] 
At the 60-day treatment time point, it was observed that HVAD+ECM 
produced the greatest absolute regional blood flows than the single therapies. In 
comparison to the control heart failure group, the 60 day treatment groups 
demonstrated much greater organ perfusion.  Next, in Figure 31, regional blood 
flow was compared at partial support and VAD failure conditions at the 60 day 
chronic treatment time point. It is shown that partial support HVAD+ECM had the 
greatest end-organ perfusion in the liver, kidney, bowel, lung, and skin, While 
VAD failure HVAD only had the greatest organ perfusion in the myocardial 
tissues and brain.  In Figure 32, the 60 day chronic treatment time point was 
normalized to the pre-embolization baseline. 
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Figure 31:  A comparison of regional blood flow in each tissue type for HVAD and HVAD+ECM 
experimental treatment groups at partial support settings and device failure at 60 day chronic 
treatment 
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Figure 32:  A comparison of regional blood flow, normalized to pre-embolization values, in each 
tissue type for (A) 60 day chronic treatment groups and (B) HVAD and HVAD+ECM treatment 
groups at partial support settings and device failure 
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When normalized, the trend indicated that the HVAD+ECM treatment 
group produced greater end-organ perfusion in the liver, kidney, spleen, skin, 
brain stem, cerebellum and aorta.  The ECM only group had greater perfusion in 
the myocardial tissue (ventricular septum, M1, M2, M3, and overall LV) and 
skeletal muscle. HVAD-only produced the lowest relative regional blood flows. 
1 
2 
3 
E. BrdU - Cell Proliferation 
1 
2 
Each myocardial specimen was stained for BrdU, cellular nuclei, and 
sarcomeric actin (SA), an indicator of mature myocytes. Total BrdU+ and BrdU+ 
cells were counted in LV and RV tissue samples.  Figure 33 is an example of a 
resulting fluorescent image. The resulting cellular counts are plotted in Figure 34. 
 
Figure 33:  Fluorescently labeled myocardium (top left) nuclei, (top right) BrdU, (bottom left) 
sarcomeric actin, and (bottom right) overlay 
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Figure 34:  Cellular counts in right ventricle, left ventricle lateral, and left ventricle anterior for (A) 
total BrdU positive cells, (B) both BrdU and sarcomeric actin positive cells, and (C) BrdU positive 
and sarcomeric actin negative cells 
The results show that the HVAD+ECM group had the greatest total 
number of BrdU+ cell in all three tissue types.  There was not a significant 
difference for BrdU+/SA+ among the treatment groups. LV lateral appears to 
have the greatest number of BrdU+/SA+ cells 
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F. Histopathology 
1 
2 
A histological review was performed by a licensed veterinary pathologist 
and the results are summarized below.  Shown in Figure 35, fibrotic regions in 
the tissue samples were determined by HE staining.  Fibrotic regions were 
marked and percent tissue fibrosis was calculated. The results of the HE stain 
are summarized in Table 7 and plotted in Figure 36 and 37.  
 
Figure 35:  Sample histopathology photomicrographs for left ventricular free wall, (top) HVAD, 
(middle) ECM, and (bottom) HVAD+ECM; outlined regions mark areas of fibrosis 
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Table 15:  Percent fibrosis in each tissue sample for each of the 60 day treatment groups 
Fibrosis (%) ECM HVAD HVAD+ECM 
LV Free Wall 20 ± 7.1 35 ± 21 15 ± 14 
RV Free Wall 10 ± 0 5 ± 0 7.5 ± 3.5 
L Atrium 13 ± 3.5 18 ± 18 7.5 ±3.5 
R Atrium 20 ± 0 28 ± 32 38 ± 18 
IV Septum 5 ± 7.5 10 ± 7.1 7.5 ± 3.5 
Papillary Muscle 13 ± 18 35 ± 21 10 ± 0 
 
 
Figure 36:  A comparison of the percent fibrosis in the left and right ventricle for the normal 
control and heart failure control group  
 
Figure 37:  A comparison of the percent fibrosis in each 60 day chronic therapy treatment group 
for LV free wall, RV free wall, left atrium, right atrium, interventricular septum, and papillary 
muscle 
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The results of the fibrosis study are comparable to the results of the 
control study.  The treatment group ventricles had decreased levels of fibrosis in 
the ventricles as compared to the heart failure control. Overall, the HVAD+ECM 
group had the least percentage of fibrosis in each tissue sample except for the 
right atrium.  The major histopathologic findings for each animal are summarized 
in Table 8.  The ECM only group had the fewest pathological changes. 
Table 16:  Histopathologic findings for individual animals (X indicates the presence of a lesion) 
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V. DISCUSSION 
1 
2 
3 
With regards to weight analysis, the heart failure animals saw a minimal 
reduction in weight (17±17%) as compared to the baseline and control groups.  
This reduction has a large variance indicating that weight gain per day was 
diverse and the sample size was not  large enough to demonstrate significant 
values.  However at the 60 day treatment time point, the ECM only group 
regained the original rate of growth while the HVAD and HVAD+ECM group 
remained in the cachexic state.   
Although, the HVAD+ECM group did not regain the normal rate of growth, 
analysis of EF indicates that HVAD+ECM group demonstrated the greatest EF 
with 60 day chronic treatment (75 ± 4.2%). However, when normalized to the 
baseline EF, ECM only had the greatest restoration of EF (96.6±11.1%).  The 
limitations of the normalized data is that the HVAD only and HVAD+ECM group 
had a baseline n=1 because of missing values.  Therefore, there is significant 
uncertainty in the normalized values.  All three experimental groups at the 
treatment time had significantly larger EF than the heart failure time point and the 
60 day heart failure control group, indicating that all three treatments feasibly 
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treat HF and encourage greater ventricular contractility than in the heart failure 
control. Using a the Tukey Test (95% confidence), it was found that EF at heart 
failure was significantly different from baseline and treatment, but treatment was 
not significantly different from baseline. The HVAD and HVAD+ECM were not 
significantly different from each other, but were different from the ECM group.  
With a larger sample size, subtle differences between treatment groups are 
expected to be more apparent. 
Along with EF analysis, the LVVol analysis yield similar results. When 
normalized to animal weight ES LVVol was significant for both treatment and 
time point.  The ECM only group had a larger normalized ES LVVol than the 
HVAD only group, and the heart failure time point was significantly different than 
the baseline and 60 day treatment.  HVAD only and HVAD+ECM had the 
smallest normalized ES LVVol indicting that the MCS may have helped to reduce 
LV dilation and systolic dysfunction over the ECM only group. A larger sample 
size is needed to demonstrate significance for the interaction of treatment type 
and time point.1 
The results of the hemodynamic tests show an increase in ED and ES 
LVP, (+/-) dP/dt, ED and ES AoP, and AoP pulse pressure for all 60 day 
treatment groups in comparison to the heart failure control group.  The ECM only 
group showed the largest increase in LVP average and peak pressures.  This is 
consistent with what is expected because MCS is used to unload the ventricle, 
reduce pressure, and reduce wall stress.  Without MCS, the ECM only group 
experienced higher LVP pressures. The HVAD only group demonstrated the 
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greatest rate of pressure changes during diastole and systole indicating greater 
contractile function.  When comparing the HVAD support settings, there is an 
apparent drop in AoP pulse pressure and an increase in average AoP with 
increasing HVAD motor speed.  This trend is expected.  With increasing support 
from a continuous flow device, there is less pulse from native ventricular 
contraction. 
However it is interesting to note the associated pressure waveforms in 
Figure 23. The maximum support level studied, 3600 RPM, reduced aortic pulse 
pressure, but is not considered full support.  The pressure waveforms in indicate 
that even though AoP pulsitility is minimized at 3600 RPM, peak LVP reaches 
AoP, meaning that the pressure equilibrium is reached and surpassed.  This 
causes the aortic valve to open with each ventricle contraction.  Therefore, the 
HVAD support at 3600 RPMs is considered only partial support. Full support 
(continuous complete unloading) waveforms are shown previously in Figure 8. 
In terms of cardiac function, the RBF results showed interesting trends as 
to how each treatment group aided in organ perfusion.  The HVAD+ECM group 
was shown to produce the greatest overall RBF than the single therapies, 
suggesting that the combination therapy provided the greatest end-organ 
perfusion. It is shown that partial support HVAD+ECM had the greatest end-
organ perfusion in the liver, kidney, blood, lung, and skin. When the 60 day 
treatment data is normalized to the pre-embolization baseline, the HVAD+ECM 
treatment group produced greater end-organ perfusion in the liver, kidney, 
spleen, skin, brain stem, cerebellum and aorta.  The ECM only group had greater 
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perfusion in the myocardial tissue (ventricular septum, M1, M2, M3, and overall 
LV) and skeletal muscle.  The fact that the ECM group had the greatest 
myocardial profusion may support the previous findings that suggest that ECM 
encourages revascularization of tissue[53].  The ECM group is also expected to 
have greater myocardial perfusion because the ECM only treatment does not 
allow for mechanical unloading.  Rather the myocardial tissue is experiencing 
more stress and as a result more blood flow is diverted to the region to meet 
metabolic demand. 
Significant findings in the analysis of BrdU staining are limited.  The lab 
reported a low labeling yield for BrdU in all three tissue types, suggesting that the 
administration technique was not allowing for full saturation of proliferating cells. 
However, with the cells that were labeled, promising trends emerged. The results 
show that the HVAD+ECM group had the greatest total number of BrdU+ cell in 
all three tissue types. However, there was not a significant difference for 
BrdU+/SA+ (proliferating myocytes) among the treatment groups. Therefore, 
there was a significant amount of BrdU+/SA- cells labeled.   
This could indicate a few things.  Firstly, the SA- cells could be of a 
different cell type such as a proliferative fibroblast that has invaded the damaged 
myocardium and is actively depositing scar tissue.  Secondly, in accordance with 
previous ECM scaffold studies, the ECM scaffold had attracted circulating 
progenitor cells.  Because SA is an indicator of a mature myocycte, these 
progenitor cells would not be labeled. In order to meaningfully interpret the BrdU 
findings more studies have to be performed.  If there was a significant 
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proliferative cardiomyocyte progenitor cell population, administering BrdU on a 
later time scale (90 days) would allow for further cellular differentiation and 
myocyte turn over. Also in future studies, it would be practical to stain for other 
cell types, including fibroblasts, to determine if relative cellular proliferation is due 
to the inflammation response involved in heart failure rather than myocardial 
regeneration.3 
While the BrdU cellular proliferation analysis allowed room for significant 
uncertainty, the histopathology results were an accurate measurement of fibrosis 
and scar tissue formation.  According to the data, the HVAD+ECM treatment 
group had the lowest instance of fibrosis in LV free wall, left atrium, and papillary 
muscle.  The HVAD group had the lowest percent of fibrosis for the RV free wall.  
Overall HVAD+ECM and ECM groups had less fibrosis than the HVAD only 
group suggests the ECM scaffold helped to rebuild fibrotic scar tissue.  This 
finding has extremely exciting regenerative implications.  With a 90 day study, 
further reduction in fibrosis can indicate scar tissue remodeling.  
According to the summary of the histopathologic findings, shown in Table 
8, the ECM only group had the fewest/mild instances of lesions. According to the 
pathology report, HVAD implant was associated with pericarditis and myocarditis 
as a reaction to a foreign body (implant and suture material), moderate pleuritis, 
and thrombosis in the cardiac or pulmonary arteries.  The ECM injection was 
associated with early evidence of heart failure in the lung with accumulation of 
heart failure cells.  Overall the vessel walls and heart valves were relatively 
unchanged in each group.  The ECM only group had fewer histopathic changes 
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than those with an HVAD implant.  All treatment groups had moderate 
myocardial fibrosis and mild pulmonary edema, a sign of early right HF.  It is 
unclear if the right HF was in the process of developing or healing.  A second 90 
day treatment study will be useful in determining if right HF further progresses or 
recovers with treatment.    
While very few of the results are significant to a 95% degree of 
confidence, the aim of the study was met.  Overall, the results indicated the 
feasibility of successful combination MCS and regenerative heart failure therapy.  
The rational of the study is to gather sufficient preliminary data to demonstrate 
the possible benefits of combination therapy.  These results will be incorporated 
into a larger study that will aim to support the hypothesis with significant 
confidence.  The associated 90 day study, Figure 12, has been initiated, allowing 
for the collection of vital information on an extended timeline. The results of this 
60 day study will be used in conjunction with the 90 day study to further analyze 
the timeline of myocardial recovery and regeneration. The expected results have 
significant clinical implications in the development of new heart failure treatment 
strategies.  With the expected increase in patients with CVD and HF, it is more 
important than ever to develop methods to, not only treat and sustain patients 
with end stage HF, but to develop methods for possible HF recovery. 
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APPENDIX I:  INDIVIDUAL DATA 
1 
2 
3 
Table 17:  Rate of Weight Gain Calculations 
 
 
ECM HVAD HVAD+ECM 
 
 
5086 5089 5087 6014 5088 5472 
Ti
m
e
 (
d
ay
s)
 Arrival – HF embol. 20 15 51 13 14 29 
HF - Treatment 106 103 35 34 90 32 
Treatment + 14 d 14 14 14 14 14 14 
15d - 60d 48 49 46 45 48 48 
W
e
ig
h
t 
(k
g)
  Arrival  50 66 50 72 62 51 
Embol 67 76 94 82 74 70 
Pre-treatment 128 154 117 104 142 85 
Post-treatment - 14d 130 157 122 111 139 94 
Final 167 194 150 130 170 123 
W
e
ig
h
t 
G
a
in
 
(k
g)
 
Pre-Emboli  17 10 44 10 12 19 
Heart Failure 61 78 23 22 68 15 
14 day recovery 2 3 5 7 -3 9 
Treatment 37 37 28 19 31 29 
R
at
e
 
(k
g/
d
ay
) 
Pre-Emboli  0.850 0.667 0.863 0.769 0.857 0.655 
Heart Failure 0.575 0.757 0.657 0.647 0.756 0.469 
14 day recovery 0.143 0.214 0.357 0.500 -0.214 0.643 
Treatment 0.771 0.755 0.609 0.422 0.646 0.604 
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Table 18:  BCS Scores at multiple time points compared with post-op day (POD) 
 
ECM HVAD HVAD+ECM 
 
5086 5089 5087 6014 5088 7472 
Time Point POD BCS POD BCS POD BCS POD BCS POD BCS POD BCS 
Baseline 0 2.5 0 2 0 2.5 0 2.5 0 2 0 2 
1 17 2.5 18 2.5 7 2.5 5 2.5 15 2 6 2 
2 35 2.5 36 2.5 13 2.5 11 2.5 31 2.5 11 2 
3 53 2.5 55 2.5 20 2.5 17 2.5 46 2.5 17 2.5 
4 70 2.5 73 2.5 26 2.5 22 2.5 62 2.5 23 2 
5 88 2.5 92 3 33 2.5 28 2.5 77 2.5 29 2 
Chronic HF 106 2 110 3 39 2.5 34 2.5 92 3 35 2 
7 116 2 120 2.5 49 2.5 44 2.5 102 3 45 2.5 
8 127 2 131 2.5 59 2.5 54 2.5 112 3 56 2.5 
9 137 2 141 2.5 69 2.5 64 2.5 122 3 66 2.5 
10 148 2 152 2.5 79 2.5 74 2.5 133 3 77 2.5 
11 158 2.5 162 3 89 2.5 84 2.5 143 3 87 2.5 
60 day treat 169 2.5 173 3 99 2.5 94 2.75 153 3 98 2.5 
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Table 19:  (top) Ejection fraction and (bottom) left ventricle volume (end diastolic and end 
systolic) at various time points and animal conditions 
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Table 20:  Hemodynamic parameters for individual test subjects 
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Table 21:  Hemodynamic parameters for individual test subjects (cont.) 
 
 
 
Table 22:  HE staining results showing percent fibrosis for individual test subjects 
 
ECM HVAD HVAD+ECM 
Tissue 5089 5086 5087 6014 5472 5088 
LVFW 25.0% 15.0% 50.0% 20.0% 5.0% 25.0% 
RVFW 10.0% 10.0% 5.0% 5.0% 5.0% 10.0% 
L atrium 10.0% 15.0% 30.0% 5.0% 5.0% 10.0% 
R atrium 20.0% 20.0% 50.0% 5.0% 25.0% 50.0% 
IVS 10.0% 0.0% 5.0% 15.0% 10.0% 5.0% 
Papillary  0.0% 25.0% 50.0% 20.0% 10.0% 10.0% 
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Table 23:  Regional blood flow calculation (ml/min/gram tissue) for each tissue specimen in 
individual test subjects at various time points and HVAD settings 
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Table 24:  BrdU+ and BrdU+SA+ cell count (per 10,000 nuclei) in the right ventricle and lateral 
and anterior left ventricle for each test subject 
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1 
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3 
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6 
7 
8 
9 
10 
APPENDIX II:  ANALYSIS OF VARIANCE 
1 
2 
3 
A) Weight Gain Per Day 
Analysis of Variance for Rate Weight Gain (kg/day), using Adjusted SS for Tests 
Source                DF   Seq SS   Adj SS   Adj MS     F      P 
Treatment              2  0.01769  0.01769  0.00885  0.68  0.532 
Time Point             2  0.07620  0.07620  0.03810  2.91  0.106 
Treatment*Time Point   4  0.05165  0.05165  0.01291  0.99  0.461 
Error                  9  0.11766  0.11766  0.01307 
Total                 17  0.26320 
S = 0.114339   R-Sq = 55.30%   R-Sq(adj) = 15.56% 
 
Analysis of Variance for Normalized Rate Weight Gain (kg/day), using Adjusted 
SS for Tests 
Source                DF   Seq SS   Adj SS   Adj MS     F      P 
Treatment              2  0.08331  0.08331  0.04165  2.15  0.172 
Time Point             2  0.11322  0.11322  0.05661  2.93  0.105 
Treatment*Time Point   4  0.08625  0.08625  0.02156  1.11  0.408 
Error                  9  0.17419  0.17419  0.01935 
Total                 17  0.45697 
S = 0.139120   R-Sq = 61.88%   R-Sq(adj) = 28.00% 
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B) Ejection Fraction 
 
Analysis of Variance for EF (%), using Adjusted SS for Tests 
 
Source                DF   Seq SS   Adj SS   Adj MS      F      P 
Treatment              2   528.37   437.88   218.94  11.37  0.009 
Time Point             2  4199.39  3816.68  1908.34  99.13  0.000 
Treatment*Time Point   4    77.14    77.14    19.29   1.00  0.474 
Error                  6   115.50   115.50    19.25 
Total                 14  4920.40 
S = 4.38748   R-Sq = 97.65%   R-Sq(adj) = 94.52% 
 
Grouping Information Using Tukey Method and 95.0% Confidence 
Treatment  N   Mean  Grouping 
2          4  67.00  A 
1          5  63.67  A 
0          6  54.17    B 
Time 
Point  N   Mean  Grouping:  
1      4  76.67  A 
3      6  70.33  A 
2      5  37.83    B 
Means that do not share a letter are significantly different. 
 
 
Analysis of Variance for Normalized Ejection Fraction, using Adjusted SS for 
Tests 
Source                DF   Seq SS   Adj SS   Adj MS       F      P 
Treatment              2  0.04664  0.04664  0.02332    5.53  0.099 
Time Point             2  1.00323  0.92498  0.46249  109.65  0.002 
Treatment*Time Point   4  0.08072  0.08072  0.02018    4.78  0.115 
Error                  3  0.01265  0.01265  0.00422 
Total                 11  1.14325 
S = 0.0649444   R-Sq = 98.89%   R-Sq(adj) = 95.94% 
 
 
 
C) LV Volume 
Analysis of Variance for ED LVvol (mL), using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2   14861   18446    9223  2.09  0.205 
Time Point             2   68245   60198   30099  6.81  0.029 
Treatment*Time Point   4   14528   14528    3632  0.82  0.556 
Error                  6   26527   26527    4421 
Total                 14  124162 
S = 66.4925   R-Sq = 78.63%   R-Sq(adj) = 50.15% 
 
 
Analysis of Variance for ES LVvol (mL), using Adjusted SS for Tests 
Source                DF   Seq SS   Adj SS   Adj MS      F      P 
Treatment              2   7053.7   8075.2   4037.6   4.47  0.065 
Time Point             2  37031.6  33281.6  16640.8  18.43  0.003 
Treatment*Time Point   4   3446.2   3446.2    861.5   0.95  0.495 
Error                  6   5417.5   5417.5    902.9 
Total                 14  52948.9 
S = 30.0486   R-Sq = 89.77%   R-Sq(adj) = 76.13% 
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Analysis of Variance for Normalized ED LVvol (mL/kg), using Adjusted SS for 
Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2  1.1497  1.2851  0.6426  1.98  0.218 
Time Point             2  1.9207  2.1251  1.0625  3.28  0.109 
Treatment*Time Point   4  0.4385  0.4385  0.1096  0.34  0.843 
Error                  6  1.9429  1.9429  0.3238 
Total                 14  5.4518 
S = 0.569042   R-Sq = 64.36%   R-Sq(adj) = 16.85% 
 
 
Analysis of Variance for Normalized ES LVvol (mL/kg), using Adjusted SS for 
Tests 
Source                DF   Seq SS   Adj SS   Adj MS      F      P 
Treatment              2  0.60836  0.64035  0.32018   6.19  0.035 
Time Point             2  3.38490  3.19406  1.59703  30.90  0.001 
Treatment*Time Point   4  0.27243  0.27243  0.06811   1.32  0.363 
Error                  6  0.31015  0.31015  0.05169 
Total                 14  4.57584 
S = 0.227358   R-Sq = 93.22%   R-Sq(adj) = 84.18% 
 
Grouping Information Using Tukey Method and 95.0% Confidence for N ES LVvol 
Treatment  N   Mean  Grouping:  
0          6  1.018  A 
2          4  0.702  A B 
1          5  0.532    B 
Time 
Point  N   Mean  Grouping 
2      5  1.438  A 
3      6  0.503    B 
1      4  0.310    B 
Means that do not share a letter are significantly different. 
 
D) Microspheres 
Analysis of Variance for Liver, using Adjusted SS for Tests 
Source                DF   Seq SS   Adj SS   Adj MS     F      P 
Treatment              2  0.02710  0.04143  0.02071  0.63  0.570 
Time Point             2  0.21935  0.29056  0.14528  4.41  0.079 
Treatment*Time Point   4  0.20597  0.20597  0.05149  1.56  0.314 
Error                  5  0.16459  0.16459  0.03292 
Total                 13  0.61701 
S = 0.181434   R-Sq = 73.32%   R-Sq(adj) = 30.64% 
 
 
Analysis of Variance for Kidney, using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2   8.575   8.485   4.243  0.69  0.542 
Time Point             2  27.715  27.493  13.747  2.25  0.201 
Treatment*Time Point   4   7.221   7.221   1.805  0.30  0.870 
Error                  5  30.577  30.577   6.115 
Total                 13  74.089 
S = 2.47295   R-Sq = 58.73%   R-Sq(adj) = 0.00% 
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Analysis of Variance for Spleen, using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2  0.1109  0.0778  0.0389  0.20  0.825 
Time Point             2  0.4076  0.4332  0.2166  1.11  0.399 
Treatment*Time Point   4  0.2676  0.2676  0.0669  0.34  0.839 
Error                  5  0.9762  0.9762  0.1952 
Total                 13  1.7622 
S = 0.441856   R-Sq = 44.61%   R-Sq(adj) = 0.00% 
 
 
Analysis of Variance for RV, using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2   2.265   2.079   1.039  0.56  0.601 
Time Point             2   1.569   0.692   0.346  0.19  0.834 
Treatment*Time Point   4   3.375   3.375   0.844  0.46  0.765 
Error                  5   9.200   9.200   1.840 
Total                 13  16.408 
S = 1.35647   R-Sq = 43.93%   R-Sq(adj) = 0.00% 
 
 
Analysis of Variance for LV, using Adjusted SS for Tests 
Source                DF   Seq SS   Adj SS   Adj MS     F      P 
Treatment              2  0.06253  0.09766  0.04883  2.20  0.206 
Time Point             2  0.21570  0.20944  0.10472  4.72  0.070 
Treatment*Time Point   4  0.28666  0.28666  0.07166  3.23  0.115 
Error                  5  0.11087  0.11087  0.02217 
Total                 13  0.67576 
S = 0.148912   R-Sq = 83.59%   R-Sq(adj) = 57.34% 
 
 
Analysis of Variance for Septum, using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2  0.2976  0.4576  0.2288  1.74  0.267 
Time Point             2  0.3623  0.3339  0.1669  1.27  0.358 
Treatment*Time Point   4  0.6576  0.6576  0.1644  1.25  0.397 
Error                  5  0.6572  0.6572  0.1314 
Total                 13  1.9748 
S = 0.362549   R-Sq = 66.72%   R-Sq(adj) = 13.47% 
 
 
Analysis of Variance for M1, using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2  0.8073  0.7745  0.3872  0.51  0.627 
Time Point             2  1.4196  0.9500  0.4750  0.63  0.570 
Treatment*Time Point   4  1.3194  1.3194  0.3299  0.44  0.778 
Error                  5  3.7692  3.7692  0.7538 
Total                 13  7.3156 
S = 0.868240   R-Sq = 48.48%   R-Sq(adj) = 0.00% 
 
 
Analysis of Variance for M2, using Adjusted SS for Tests 
Source                DF   Seq SS   Adj SS   Adj MS     F      P 
Treatment              2  0.21536  0.20798  0.10399  3.43  0.115 
Time Point             2  0.26681  0.22379  0.11189  3.69  0.104 
Treatment*Time Point   4  0.29674  0.29674  0.07418  2.45  0.177 
Error                  5  0.15166  0.15166  0.03033 
Total                 13  0.93057 
S = 0.174161   R-Sq = 83.70%   R-Sq(adj) = 57.63% 
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Analysis of Variance for M3, using Adjusted SS for Tests 
Source                DF   Seq SS   Adj SS   Adj MS     F      P 
Treatment              2  0.22079  0.26653  0.13327  5.51  0.054 
Time Point             2  0.14690  0.13082  0.06541  2.70  0.160 
Treatment*Time Point   4  0.43824  0.43824  0.10956  4.53  0.064 
Error                  5  0.12098  0.12098  0.02420 
Total                 13  0.92690 
S = 0.155548   R-Sq = 86.95%   R-Sq(adj) = 66.07% 
 
 
Analysis of Variance for Bowel, using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2  0.2590  0.2611  0.1305  0.74  0.524 
Time Point             2  0.7426  0.8700  0.4350  2.46  0.180 
Treatment*Time Point   4  0.3873  0.3873  0.0968  0.55  0.710 
Error                  5  0.8841  0.8841  0.1768 
Total                 13  2.2731 
S = 0.420496   R-Sq = 61.11%   R-Sq(adj) = 0.00% 
 
 
 
Analysis of Variance for Lung, using Adjusted SS for Tests 
Source                DF   Seq SS  Adj SS  Adj MS     F      P 
Treatment              2   2.4616  2.2107  1.1054  1.94  0.237 
Time Point             2   2.3373  1.3608  0.6804  1.20  0.376 
Treatment*Time Point   4   2.6569  2.6569  0.6642  1.17  0.424 
Error                  5   2.8431  2.8431  0.5686 
Total                 13  10.2989 
S = 0.754069   R-Sq = 72.39%   R-Sq(adj) = 28.22% 
 
 
 
Analysis of Variance for Skin, using Adjusted SS for Tests 
Source                DF    Seq SS    Adj SS    Adj MS     F      P 
Treatment              2  0.003941  0.003877  0.001939  1.56  0.298 
Time Point             2  0.004487  0.002524  0.001262  1.01  0.427 
Treatment*Time Point   4  0.008353  0.008353  0.002088  1.68  0.290 
Error                  5  0.006222  0.006222  0.001244 
Total                 13  0.023004 
S = 0.0352763   R-Sq = 72.95%   R-Sq(adj) = 29.68% 
 
 
Analysis of Variance for Skeletal Muscle, using Adjusted SS for Tests 
Source                DF   Seq SS   Adj SS   Adj MS     F      P 
Treatment              2  0.15313  0.16415  0.08207  2.50  0.177 
Time Point             2  0.00822  0.00727  0.00364  0.11  0.897 
Treatment*Time Point   4  0.01289  0.01289  0.00322  0.10  0.979 
Error                  5  0.16443  0.16443  0.03289 
Total                 13  0.33867 
S = 0.181347   R-Sq = 51.45%   R-Sq(adj) = 0.00% 
 
 
Analysis of Variance for Brain Stem, using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2  1.5243  2.1712  1.0856  4.80  0.069 
Time Point             2  0.9756  1.0284  0.5142  2.27  0.199 
Treatment*Time Point   4  1.3700  1.3700  0.3425  1.51  0.326 
Error                  5  1.1309  1.1309  0.2262 
Total                 13  5.0008 
S = 0.475578   R-Sq = 77.39%   R-Sq(adj) = 41.20% 
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Analysis of Variance for Cerebellum, using Adjusted SS for Tests 
Source                DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment              2  11.930  16.321   8.160  3.86  0.097 
Time Point             2   4.898   4.657   2.328  1.10  0.402 
Treatment*Time Point   4   7.595   7.595   1.899  0.90  0.528 
Error                  5  10.576  10.576   2.115 
Total                 13  34.998 
S = 1.45434   R-Sq = 69.78%   R-Sq(adj) = 21.43% 
 
 
Analysis of Variance for Aorta, using Adjusted SS for Tests 
Source                DF     Seq SS     Adj SS     Adj MS     F      P 
Treatment              2  0.0001161  0.0001093  0.0000547  0.13  0.884 
Time Point             2  0.0079922  0.0076947  0.0038474  8.89  0.023 
Treatment*Time Point   4  0.0006029  0.0006029  0.0001507  0.35  0.836 
Error                  5  0.0021638  0.0021638  0.0004328 
Total                 13  0.0108750 
S = 0.0208027   R-Sq = 80.10%   R-Sq(adj) = 48.27% 
 
Analysis of Variance for PA, using Adjusted SS for Tests 
Source                DF    Seq SS    Adj SS    Adj MS     F      P 
Treatment              2  0.048196  0.045933  0.022966  3.13  0.131 
Time Point             2  0.059793  0.040185  0.020093  2.74  0.157 
Treatment*Time Point   4  0.053307  0.053307  0.013327  1.82  0.263 
Error                  5  0.036640  0.036640  0.007328 
Total                 13  0.197936 
S = 0.0856033   R-Sq = 81.49%   R-Sq(adj) = 51.87% 
 
E) BrdU 
Analysis of Variance for BrdU+, using Adjusted SS for Tests 
Source             DF    Seq SS    Adj SS   Adj MS      F      P 
Treatment           2  17039687  17039687  8519843  56.31  0.000 
Tissue              2   2174346   2174346  1087173   7.19  0.001 
Treatment*Tissue    4   2791537   2791537   697884   4.61  0.001 
Error             171  25870951  25870951   151292 
Total             179  47876521 
S = 388.963   R-Sq = 45.96%   R-Sq(adj) = 43.44% 
 
Analysis of Variance for BrdU+SA+, using Adjusted SS for Tests 
Source             DF  Seq SS  Adj SS  Adj MS     F      P 
Treatment           2    2414    2414    1207  0.67  0.515 
Tissue              2   26130   26130   13065  7.21  0.001 
Treatment*Tissue    4    3126    3126     781  0.43  0.786 
Error             171  309818  309818    1812 
Total             179  341488 
S = 42.5653   R-Sq = 9.27%   R-Sq(adj) = 5.03% 
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